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High performance affinity chromatography (HPAC) is a technique that uses a biologically-
related agent such as a transport protein or an antibody as the stationary phase in an HPLC system.  
In recent years, HPAC has been shown to be a valuable bioanalytical tool for studying solute-
protein interactions.  Human serum albumin (HSA), the most abundant protein in blood (with 
concentrations of 35 to 50 mg/mL in serum), has been shown to interact with many drugs, affecting 
their transport, excretion and metabolism. A physical method for immobilizing proteins in HPAC 
supports has been optimized in this dissertation by using HSA as a model protein.  
This method involved the encapsulation of this protein inside the pores or near the surface 
of hydrazide-activated silica by using mildly oxidized glycogen as a capping agent for the 
hydrazide groups.  Previous work has shown that this approach is able to retain the activity of the 
entrapped protein and to produce binding that is comparable to what is seen for the protein in its 
soluble form. 
The entrapment process was optimized in a slurry based-format by altering the purification 
method for the oxidized glycogen, as well as increasing the concentration of protein and decreasing 
the total reaction volume that were used in this format. Through these changes, it was possible to 
obtain HPAC stationary phases with a nine-fold increase in their retention factor for warfarin.  An 
 on-column entrapment approach was also examined, in which HSA and oxidized glycogen were 
reacted with hydrazide-activated silica in a flow-based format.  This second approach provided 
retention factors for warfarin that were up to three-fold higher than those obtained by the slurry 
method.  The ability of the on-column method to produce higher capacity stationary phases was 
then exploited for making chromatographic supports capable of separating sugars by using 
immobilized lectins. This on-column approach was also used for studying the effects of glycation 
of HSA on its binding properties with various sulfonylurea drugs that are used to treat diabetes. It 
was found that normal HSA and HSA with various levels of glycation, as immobilized by 
entrapment, did show changes in their drug binding parameters that depended on the level of 
glycation. 
Finally, organic monoliths containing silver nanoparticles (AgNPs) were placed on glass 
slides and within microchannels and used for detecting a near infrared fluorescent dye. Up to ten-
fold enhancement in the fluorescence signal of the dye was obtained for monoliths containing 
AgNPs when compared to control monoliths. This higher sensitivity can be exploited in making 
stationary phases or detection elements in microfluidic devices that can be utilized in the analysis 
of small samples and in applications such as flow-based biointeraction studies. 
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CHAPTER 1. INTRODUCTION 
1.1. HIGH PERFORMANCE AFFINITY CHROMATOGRAPHY 
High performance affinity chromatography (HPAC) is an analytical technique that 
combines the instrumentation, speed and efficiency of high performance liquid 
chromatography (HPLC) with the highly selective nature of affinity chromatography (AC) 
[1,2].  This liquid chromatographic technique uses the reversible interactions that are 
common in many biological systems, such as enzyme-substrate and antibody-antigen 
interactions.  One of the components of such a system is coupled to a chromatographic 
matrix and placed into a column where it makes up the stationary phase (or “affinity 
ligand”).  The other component is dissolved in the mobile phase and used as an applied 
target or analyte.  The interactions between the affinity ligand and the analyte are usually 
quite strong and specific, allowing for the use of affinity chromatography in the purification 
and analysis of target compounds in complex samples [1-5]. 
The affinity ligand can be either a biological agent, such as a protein, or a synthetic 
molecule that mimics some of the binding properties of a natural compound.  Examples of 
proteins that have been used as affinity ligands are human serum albumin (HSA), α1-acid 
glycoprotein (AGP), and antibodies (or immunoglobulins).  Lectins from plants are affinity 
ligands that also belong to this category.  Examples of synthetic molecules that have been 
used as affinity ligands are boronic acids, metal ion chelates and biomimetic dyes [5-7]. 
When the affinity ligand (e.g., a protein) is immobilized onto a support that is 
suitable for use in high performance liquid chromatography (e.g., porous silica beads), the 
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resulting technique is known as HPAC.  This method can be used in separations to 
conveniently isolate, measure, or study specific target-ligand interactions even when the 
applied targets are present in complex biological samples.  Automation in HPAC can allow 
a drastic reduction in analysis times and the sample sizes that are required for the study of 
biological interactions when compared with other well-established techniques such as 
ultrafiltration and equilibrium dialysis.  Another advantage of HPAC is its ability to reuse 
the same biological agent for many studies [1,2]. 
1.2. COVALENT IMMOBILIZATION AND IMMOBILIZATION 
EFFECTS 
Covalent attachment is frequently used for immobilizing a ligand to an HPAC 
support.  Functional groups such as amine, sulfhydryl, carbonyl or hydroxyl groups are 
commonly used for this process.  Among these groups, amines have been widely used in 
the immobilization of proteins to silica supports for use in HPAC [4,8-13].  The Schiff base 
method is one example of such a technique [14].  The stability of the linkage between 
amine groups on a protein and aldehyde groups on a modified support has made this 
method attractive for work with proteins and antibodies [14].  However, covalent coupling 
methods can often have issues like multisite attachment, improper ligand orientation and 
immobilization near the active site of a ligand, which can lead to a decrease in or loss of 
the ligand’s activity [5].  
Multisite attachment refers to the coupling of an affinity ligand to a support through 
more than one functional group on the same ligand.  This effect can stabilize the attachment 
of an affinity ligand to the support but can also deform the active site of the affinity ligand, 
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affecting its binding capacity.  Improper orientation occurs when the site of attachment for 
an affinity ligand is at or near its active region.  Steric hindrance occurs when this active 
site is blocked by the support or by neighboring affinity ligands.  These factors can render 
the active site more difficult to reach by the target analyte.  These problems (e.g., multisite 
attachment or improper orientation) may be present to some extent when immobilizing 
affinity ligands that are proteins and when using amine-based coupling methods, because 
amine groups may be present at many locations in such binding agents [5]. 
1.3. ENTRAPMENT 
To overcome effects such as steric hindrance and improper attachment that can 
occur during the use of covalent immobilization methods, and to obtain protein-based 
stationary phases with high activities, alternative immobilization methods based on 
entrapment have been explored [5,15-19].  This approach involves the physical 
containment or encapsulation of an affinity ligand in a support that contains small pores or 
a highly cross-linked polymer network [5].  Entrapment has been extensively used in work 
with sol-gels for drug release and for applications involving low performance separations.  
However, most of these materials are not suitable for use in HPAC because of their inability 
to withstand high pressures and their slow mass transfer properties [15-17]. 
Recent work was conducted using entrapment with HPLC-grade silica and was 
tested by using HSA as a model affinity ligand [20].  This method has been employed for 
examining the interactions of HSA with sulfonylurea drugs by HPAC [21].  The 
entrapment procedure that was used in these studies involved placing HSA into a slurry 
containing hydrazide-activated porous silica and glycogen that had been mildly oxidized 
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by treatment with periodic acid to form aldehyde groups on the glycogen.  The aldehyde 
groups on the glycogen were able to react with the hydrazide groups on the silica to form 
stable covalent bonds, while the HSA remained free in solution.  During this reaction, some 
of the HSA became entrapped in a soluble form near the surface of the support or within 
the pores of the silica particles with no apparent loss of activity.  Because glycogen is a 
large and highly branched carbohydrate polymer, the entrapped HSA was blocked by this 
polymer from leaving the support, but it was still possible for this protein to be reached by 
small molecules that could pass into and out of the pores of the support or reach its surface 
[20,21].  Besides providing good activity and avoiding many of the undesirable effects of 
covalent immobilization, this entrapment approach could be extended to other proteins and 
relatively large affinity ligands [20].  
1.4. QUANTITATIVE AFFINITY CHROMATOGRAPHY 
Although affinity chromatography was initially used for the isolation of biological 
compounds, over the past few decades a great deal of work has been done using this method 
for chemical analysis in areas such as biochemistry, pharmaceutical science, clinical 
chemistry, and environmental testing. In addition, the role of affinity chromatography in 
these fields has involved an increasing emphasis on the use of this method as a tool for 
studying the strength and rates of biological interactions, as well as in characterizing the 
number and types of binding sites that are involved in these interactions [2,4,22-24]. 
Several parts of this dissertation are concerned with the use of affinity 
chromatography and HPAC for the study and characterization of biological interactions.  
This type of application is also known as quantitative affinity chromatography or analytical 
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affinity chromatography.  One advantage of using HPAC for this type of work is the ability 
to often reuse the same preparation of an immobilized affinity ligand for multiple 
experiments.  This feature reduces the total amount of affinity ligand that is needed to 
conduct a series of experiments and reduces the cost per analysis.  In addition, using the 
same affinity ligand preparation for many experiments helps to improve the reproducibility 
and precision by minimizing batch-to-batch and run-to-run variations.  Finally, the ability 
of HPAC to make use of HPLC instrumentation allows for the automation of this method 
and reduces contamination of the columns between experiments by continuously washing 
the stationary phase with the mobile phase [25]. 
One experimental format that is used in HPAC for studying biological interactions 
is zonal elution (or “ZE”).  This method involves making small injections of a probe 
compound or the analyte into a column that contains the immobilized affinity ligand.  The 
outcome of this experiment is a peak for the probe or analyte that can be monitored by on-
line detection.  The most common parameter that is obtained from this chromatogram is 
the retention time of the injected compound, which is then used to help characterize the 
binding of this compound to the affinity ligand in the presence of a given mobile phase 
(e.g., a buffer that mimics physiological conditions or the natural environment of the 
affinity ligand) [1,25]. 
The binding between the applied analyte (A) and an affinity ligand (L) immobilized 
in a chromatographic column can be described by the following equations for a system 
with a 1:1 interaction, 
𝐴 + 𝐿 ↔ 𝐴 − 𝐿    (1.1)   𝐾𝑎 =
𝑘𝑎
𝑘𝑑
=
[𝐴−𝐿]∗
[𝐴][𝐿]∗
  (1.2)  
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where AL is the analyte-ligand complex, Ka is the association equilibrium constant 
for the formation of this complex, ka and kd are the association and dissociation rate 
constants for this complex, and [L]* or [A−L]* represent the surface concentrations of the 
affinity ligand and analyte-ligand complex at equilibrium [8,9].  These equations indicate 
that the retention of an analyte or target compound in an affinity column is determined by 
several parameters, such as the strength of the ligand-target interaction (e.g., Ka) and the 
amount of the immobilized affinity ligand that is present (e.g., [L]*).   
An analyte’s retention in an affinity column can be described experimentally by its 
retention factor k, which is calculated as follows, 
    𝑘 =
(𝑡𝑟−𝑡𝑚)
𝑡𝑚
     (1.3) 
where tr is the retention time of the analyte, and tm is the column void time.  The 
value of the retention factor is related to the association equilibrium constant and the 
amount of active affinity ligand in the column, as is indicated for a 1:1 reaction in Equation 
(1.4), 
    𝑘 = 𝐾𝑎
𝑚𝐿
𝑉𝑀
    (1.4) 
where mL is the moles of active affinity ligand, and VM is the column void volume.  
The ratio mL /VM in this equation is the effective concentration of the affinity ligand in the 
column [8,9].  If the mobile phase during a zonal elution experiment contains other agents 
(e.g., competing solutes), it is further possible to use this type of study to obtain information 
on how these agents may affect the analyte-ligand interaction [8,9,25]. 
Another important format that can be used for studying a biological interaction by 
HPAC is frontal analysis (or “FA”).  In this approach, a solution containing a known 
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concentration of a target analyte is continuously applied to an affinity column at a constant 
flow rate.  As the target binds to the immobilized affinity ligand, the column becomes 
saturated and the amount of target that is eluting from the column gradually increases.  This 
forms a breakthrough curve, which is essentially a titration of the active ligand in the 
column.  If relatively fast association and dissociation kinetics are present on the time scale 
of this experiment, the mean position of the breakthrough curve can be used to determine 
the amount of active affinity ligand that is in the column and the association equilibrium 
constant of the affinity ligand for the target [5,25]. 
When frontal analysis is used to study a biological interaction, the moles of the 
target that are required to reach the mean point of the breakthrough curve are often 
measured at several concentrations of the applied target, and the resulting data are fit to 
various models to determine if this interaction involves one or more binding sites.   The 
model that best describes the data is then used to determine the equilibrium constant(s) for 
the target-ligand interactions and the amount of each type of binding site in the column.  
For example, in the case of a target analyte (A) that has a single type of binding site on an 
affinity ligand (L), the frontal analysis results should provide a good fit to the following 
equation, 
       
1
𝑚𝐿𝑎𝑝𝑝
=
1
𝐾𝑎𝑚𝐿[𝐴]
+
1
𝑚𝐿
   (1.5) 
where mLapp is the apparent moles of the analyte that are required to reach the mean 
breakthrough point for the column at a given molar concentration for the applied analyte, 
[A].  The parameters Ka and mL in Equation (1.5) are the same as described earlier and can 
be determined from the slope and intercept of a best-fit line to the data for a system with a 
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single type of binding site.  The goodness of the fit for the data to this equation can be 
assessed by using such tools as the correlation coefficient and the sum of the squares of the 
residuals.  These and other tools can also be used to compare the fit of the data to other 
possible models, such as one involving two different types of binding sites [10,13,25]. 
The binding capacity of an affinity column can be determined from the value of mL 
that is obtained by frontal analysis [1,25,26].  When determining the binding capacity in 
this way, it is important to use a relatively slow flow rate that ensures that all of the applied 
analyte has sufficient time to interact with the immobilized affinity ligand [5]. The specific 
activity of the immobilized ligand can be found by dividing the measured binding capacity 
by the total amount of immobilized affinity ligand that is present.  For instance, if the 
affinity ligand is a protein, the total amount of the binding agent that is present can be 
measured by an independent method such as a bicinchoninic acid (BCA) protein assay 
[5,18]. 
1.5. OVERALL GOALS AND SUMMARY OF WORK 
It has been demonstrated recently that the entrapment of affinity ligands on 
hydrazide-activated silica, by capping this support with oxidized glycogen, can be a 
valuable approach for immobilizing proteins such as HSA for HPAC [20,21].  However, 
this method still needs further optimization for its use with alternative affinity ligands and 
in new applications.  To expand the use of this technique for preparing other HPAC 
stationary phases, it is necessary to conduct studies to answer the following questions.  
First, “What methods can be used to increase the amount of the entrapped affinity ligand?”  
Second, “What are some novel applications of affinity columns that have been prepared by 
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entrapment, such as with regards to the study of biological interactions?”  Third, “What are 
some alternative ways of carrying out the entrapment process?” 
There are several benefits to seeking the answers to these questions.  One possible 
outcome from this type of research would be the ability to prepare affinity microcolumns 
that are suitable for the analysis of extremely small samples or that could achieve low limits 
of detection.  The use of entrapment to prepare small affinity columns with high binding 
capacities would also be useful in situations where a limited amount of ligand is available, 
such as in the immobilization of proteins from individual samples of human serum.  The 
creation of new approaches for entrapment, such as the use of on-line systems for column 
preparation, would be useful in automating these methods and would also be of interest in 
applications such as personalized medicine for studies of protein-drug interactions and the 
measurement or characterization of biomarkers in samples that are taken from individuals 
with diseases such as diabetes or cancer. 
Chapter 2 of this dissertation will look at ways for increasing the amount of a 
protein that can be immobilized through entrapment.  The optimization of a flow-based 
entrapment procedure will be described in Chapter 3.  A fast method for studying drug-
protein binding, as based on entrapped protein columns, will be presented in Chapter 4.  
Finally, a platform that can be used for on-column detection in microscale chromatography 
or post-column sensing in microfluidic devices, and using fluorescent dyes and monolithic 
supports, is examined in Chapter 5. 
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CHAPTER 2.                                                                
APPROACHES FOR INCREASING PROTEIN CONTENT 
DURING IMMOBILIZATION THROUGH ENTRAPMENT 
2.1. INTRODUCTION 
The interaction of small solutes with proteins in serum is important for many drugs 
and biological agents.  Serum proteins such as human serum albumin (HSA) and 1-acid 
glycoprotein (AGP) are known to bind to many small endogenous compounds in the body, 
as well as pharmaceutical agents.  Drug-protein interactions in serum are often significant, 
with approximately 43% of the 1500 most common drugs having at least 90% binding to 
proteins in serum.  These interactions can affect the free concentration of a drug in blood 
and can play an important role in determining the distribution, activity, excretion, and 
metabolism of such an agent in the body [1-3]. 
The study of drug-protein interactions has been carried out in the past by using 
techniques such as equilibrium dialysis, ultrafiltration, and other solution-based reference 
methods (e.g., various spectroscopic methods) [4,5].  High performance affinity 
chromatography (HPAC) is a type of affinity chromatography that utilizes solid supports 
consisting of small, rigid particles that can withstand the high pressures that are typical of 
HPLC.  These supports can provide the enhanced mass transfer properties that are needed 
in HPLC for chromatographic separations and are better suited for analytical applications 
than less rigid and larger diameter supports [7].  Supports that can be used in HPAC include 
silica, azalactone beads, hydroxylated polystyrene media, and some types of monolithic 
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columns [5,7-9].  The study of drug-protein interactions by HPAC with proteins such as 
HSA and AGP has provided binding parameters that show good agreement with values 
obtained by using soluble HSA or AGP [5]. 
One advantage of HPAC is that the same protein or binding agent preparation can 
often be used for multiple experiments.  Thus, only a small amount of a protein is often 
required in HPAC to conduct a large number of studies.  This feature is useful when a 
limited amount of the binding agent is available and helps to provide good precision by 
minimizing run-to-run variations in this binding agent.  The speed and precision of HPAC, 
as well as its ability to be automated, also make this method attractive for analytical 
applications and drug-protein binding studies [8,10-12]. 
2.1.1. Examples of binding agents for HPAC 
HSA is commonly used as an immobilized affinity ligand in HPAC to study drug-
protein binding.  HSA was used in this study as a model binding agent for identifying ways 
of improving immobilization methods (i.e., entrapment, in this case) and for achieving a 
higher protein content in columns that are to be used in HPAC.  HSA is the most abundant 
protein in serum and binds to numerous drugs and endogenous compounds.  HSA makes 
up about 60% of the total protein content in blood and has a typical concentration that 
ranges from 35 to 50 g/L.  This protein has a molar mass of 66,438 g/mol and consists of 
a single polypeptide chain of 585 amino acids, which form a structure that is stabilized by 
17 disulfide bonds.    The binding of drugs to serum proteins like HSA often improves their 
solubility and is an important source of interactions that may occur between some drugs 
and endogenous agents such as fatty acids.  These agents may compete directly or indirectly 
for the same binding sites on serum proteins.  This fact makes the binding by HSA and 
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other serum proteins with drugs a subject of great interest to the pharmaceutical industry 
[1-3].  Figure 2.1 shows the structure of HSA and the location of its two major binding 
sites for drugs: Sudlow sites I and II.  Sudlow site I (also known as the warfarin-
azapropazone site) tends to bind bulky heterocyclic compounds, while Sudlow site II (also 
known as the indole-benzodiazepine site) often binds to aromatic carboxylic acids 
[8,13,14]. 
The lectin concanavalin A (Con A) was a second binding agent that was considered 
in this study.  Lectins are non-immune system proteins that are often isolated from plants 
and that can agglutinate cells and/or precipitate complex carbohydrates.  Lectins have the 
ability to bind to specific sugar moieties and have been used extensively as affinity ligands 
for fractionating and isolating glycoproteins and glycopeptides.  For example, Con A can 
bind to mannosyl and glucosyl residues, while the lectin wheat germ agglutinin (WGA) 
recognizes N-acetyl-glucosamine (GlcNAc) and sialic acid (NeuNAc) residues [15-19].   
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Figure 2.1  Structure of HSA, including its two major binding sites for drugs (i.e., Sudlow 
sites I and II).  This structure includes a molecule of the drug R-warfarin (shown 
in blue) that is bound to Sudlow site I.  The image is based on PDB entry 2bxd 
and was generated using Uniprot file ID: P02758 [6]. 
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Figure 2.2  The tetrameric structure of Con A, which was co-crystallized with the 
glycopeptide Man-WYD.  The four monomer chains are represented by 
different colors.  Each identical monomeric unit also includes Ca2+ (green), 
Mn2+ (purple) and the glycopeptide moiety.  This image is based on PDB 
entry 4czs [24]. 
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Con A is obtained from the jack bean and is the first lectin whose structure was 
determined.  It contains 237 amino acid residues and has a molar mass of 25.5 kDa.  The 
monomers of Con A can aggregate to form dimers and tetramers.  Each monomer has one 
binding site for a saccharide, one transition metal (usually Mn2+) and one Ca2+ ion [20,21].  
This binding site can interact with mannosyl and glucosyl residues of polysaccharides and 
glycoproteins (i.e., groups containing C3, C4 and C6 hydroxyl groups) and can be used to 
capture N-glycosylated peptides/proteins with broad specificity [22].  Figure 2.2 shows the 
structure of the tetrameric form of Con A [23,24]. 
2.1.2. Preparation of stationary phases for HPAC by entrapment 
The use of binding agents such as HSA or Con A in HPAC starts by immobilizing 
such a protein on a suitable support.  Porous silica with a particle size of 7 µm and a pore 
size of 300 nm was selected for use in this work as the support material, due to its good 
mechanical stability and mass transfer properties. This same material has also been used in 
many previous studies with HPAC based on the same or similar proteins to those that were 
used in this current study [3,25-27].  The particle size and pore size selected for this support 
in this study have been found in a prior report to provide the highest protein content for 
similar supports that have been prepared by using protein entrapment [28].   
The porous silica that was used as a starting material for this work was converted 
to a hydrazide-activated form for use in protein entrapment, according to a previously 
published procedure [29].  As can be seen in Figure 2.3, the first step was to treat the silica 
particles with 3-glycidoxypropyltrimethoxysilane, followed by the addition of dilute 
sulfuric acid to generate diol-bonded silica.  This material was then dried and could be 
stored as an intermediate support for several months prior to its use for protein entrapment.  
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The next step was to oxidize part of the diol-bonded silica with periodic acid to create 
aldehyde groups on the surface of the support.  This was followed by the reaction of these 
aldehyde groups with a homobifunctional hydrazide reagent to create hydrazide-activated 
silica.  In this study, oxalic dihydrazide was added to the aldehyde-activated silica to form 
the hydrazide-activated support, and sodium borohydride was later added to reduce and 
remove any aldehyde groups that were still on the support. 
In the next step of the entrapment process, a slurry containing the hydrazide-
activated silica in pH 5.0, 0.10 M potassium phosphate buffer was combined with the 
protein that was to be entrapped (e.g., HSA or Con A) and a mildly oxidized form of 
glycogen, which was used as a capping agent.  During the entrapment process, aldehyde 
groups on the oxidized glycogen were allowed to react with hydrazide groups on the 
support.  At the same time, part of the protein became trapped by the glycogen in the 
support and remained in a soluble form (see Figure 2.4) [28,30].   
Previous work has shown that this entrapment process can place proteins onto a 
silica support while maintaining their biological activity [30].  The purpose of this current 
study was to further optimize this method to increase the final protein content. A high 
protein content was desired because it should result in higher resolution and binding 
strengths for the resulting HPAC columns. The activity of HSA columns that were made 
by this method was monitored by using warfarin and carbamazepine, whose interactions 
with HSA are well-characterized [26,31-36].  The activity of columns prepared with Con 
A were measured by using 4-methylumbellipheryl α-D-mannopyranoside (MUM), which 
can be detected by absorbance or fluorescence; and has a relativley high affinity for Con 
A [17]. 
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Figure 2.3 Scheme for the preparation of hydrazide-activated silica from porous silica 
particles.  Adapted with permission from Ref. [29]. 
 
  
24 
 
 
 
 
 
 
 
 
  
25 
 
 
 
 
 
 
 
 
 
Figure 2.4 Scheme for protein entrapment by the reaction of mildly-oxidized glycogen 
with hydrazide-activated silica.  Adapted with permission from Ref. [28]. 
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2.2. EXPERIMENTAL SECTION 
2.2.1. Reagents 
HSA (essentially fatty acid free, purity ≥ 96%), Con A (type V, lyophilized powder, 
purity ≥ 99%), bovine serum albumin (BSA, fraction V, purity ≥ 96%), glycogen (bovine 
liver, type IX, total glucose ≥ 85%, dry basis), racemic warfarin (purity ≥ 98%), MUM 
(purity ≥ 96%), 4-methylumbellipheryl α-D-galactopyranoside (MUGA, purity ≥ 98%), 
periodic acid reagent (H5IO6, purity 99%), Lucifer yellow CH (LyCH, purity ≥ 85%), 
fluorescein isothiocyanate (FITC, isomer I, purity 90%) and FITC-BSA conjugate (purity 
90%) were purchased from Sigma-Aldrich (St. Louis, MO, USA).  Nucleosil Si-300 silica 
(7 m particle diameter, 300 Å pore size, 100 m2/g surface area) was obtained from 
Macherey Nagel (Düren, Germany).  A micro-bicinchoninic acid (BCA) protein assay kit 
was purchased from Pierce (Rockford, IL, USA).  All other chemicals were of the purest 
grades available.  Econo-Pac 10DG disposable desalting columns (3.3 mL void volume, 6 
kDa exclusion limit; BioRad, Hercules, CA, USA) and Vivaspin 6 ultrafiltration tubes (30 
kDa cutoff; Sartorius, Götingen, Germany) were used for glycogen purification.  All 
buffers and aqueous solutions were prepared using water from a Nanopure system 
(Barnstead, Dubuque, IA, USA).  Buffers were filtered using 0.20 μm GNWP nylon 
membranes from Millipore (Billerica, MA, USA) and were degassed by sonication under 
vacuum for at least 20 min prior to use. 
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2.2.2. Apparatus 
The chromatographic system consisted of a 1200 isocratic pump from Agilent 
(Santa Clara, CA, USA) and a Series 200 UV-Vis detector plus a vacuum degasser from 
Perkin-Elmer (Waltham, MA, USA).  Samples were injected using a Rheodyne LabPro 
valve (Cotati, CA, USA) that was equipped with a 5 µL or a 20 µL loop.  An Isotemp 9100 
circulating water bath (Fisher Scientific, Pittsburgh, PA, USA) and a water jacket from 
Alltech (Deerfield, IL, USA) were used for temperature control of the columns.  The 
chromatographic data was collected using LabView 8 software (National Instruments, 
Austin, TX, USA) and analyzed using PeakFit 4.12 (Systat Software, San Jose, CA, USA).   
A Pack in a Box system (ChromTech, Apple Valley, MN, USA) was used for 
packing the supports into columns.  A UV-160A spectrophotometer (Shimadzu, Kyoto, 
Japan) was used for the BCA protein assay.  A Cary Eclipse fluorescence 
spectrophotometer (Varian, Palo Alto, CA, USA) with a microplate reader adaptor was 
used for the protein assay based on fluorescence.  The thermogravimetric analysis of silica 
samples was performed using a TGA7 system (Perkin Elmer, Waltham, MA, USA) 
equipped with nitrogen flow for inert analysis conditions and data collection software. 
2.2.3. Preparation of entrapped protein supports 
The columns containing entrapped proteins were prepared from Nucleosil 300-7, 
HPLC-grade porous silica that had been converted into diol silica, as based on a previous 
procedure [29].  The diol silica was dried and stored for future use.  Batches of this silica 
were converted into hydrazide-activated silica by following a procedure that has also been 
described in the literature [29]. 
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The initial conditions used for entrapment were based on previous work [28] and 
involved making a slurry containing 0.08 g of hydrazide-activated silica and 0.8 mL of 10 
mg/mL HSA in pH 5.0, 0.10 M potassium phosphate buffer.  This slurry was degassed in 
a sonication bath for 10 min to ensure there was no trapped air within the support.  Next, 
0.28 mL of a 4.25 mg/ml solution of mildly oxidized glycogen in the pH 5.0, 0.10 
phosphate buffer was added (i.e., an amount equivalent to 15 mg glycogen/g silica).  The 
glycogen had been previously oxidized with periodic acid reagent in a pH 5.0 buffer 
containing 20 mM sodium acetate and 15 mM sodium chloride, as well as 17 mg of 
glycogen and 135 mg of the periodic acid reagent in 4 mL of this buffer; this oxidation was 
done for a period of 16 h in the dark.  The volume of solution for the entrapment reaction 
was then adjusted to 2 mL by adding pH 5.0, 0.10 M phosphate buffer.  This slurry was 
placed on a rotation mixer for 16 h at 4 °C.  Finally, 50 µL of oxalic dihydrazide (at a 
concentration of 1 mg/mL in pH 5.0, 0.10 M phosphate buffer) was added and allowed to 
mix with this slurry for 1 h to cap any remaining aldehyde groups on the glycogen and to 
decrease possible non-specific binding of other solutes to the column.  Control supports 
were prepared in the same manner, but with only buffer being used in place of the protein 
solution during the entrapment step. 
 Several conditions were varied in this study to increase the amount of 
entrapped protein.  These conditions included the method that was used to isolate the 
oxidized glycogen, the concentration of the protein that was used during the entrapment 
method, and the mass ratio of the protein versus silica that was utilized.  The entrapped 
protein supports and control supports were suspended in pH 7.4, 0.067 M potassium 
phosphate buffer and were downward slurry packed into 1.0 cm × 2.1 mm i.d. stainless 
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steel columns.  A pH 7.4, 0.067 M potassium phosphate buffer was used as the packing 
solution.  As the support slurry entered the column, the pressure was increased gradually 
until it reached a maximum of 3500 psi and was held at this pressure for 50 min while 
passing the pH 7.4 phosphate buffer through the column.  The pressure was then decreased 
gradually to avoid disturbing the packed support.  The column was later taken off of the 
packing system, and its assembly was completed.   Before carrying out any experiments 
with these supports, each column was placed in an HPLC system and pH 7.4, 0.067 M 
potassium phosphate buffer was passed through the column at 0.5 mL/min for at least 1 h 
or until a stable baseline was achieved. 
2.2.4. Chromatographic methods 
The application and elution buffer that was used in the chromatographic studies 
with the entrapped HSA columns was pH 7.4, 0.067 M potassium phosphate [26,31-36].  
The application and elution buffer for the work with the entrapped Con A columns was pH 
5.0, 0.50 M sodium acetate that contained 1 mM calcium chloride and 1 mM manganese 
chloride [37,38].  All columns were equilibrated with their corresponding buffer at 0.50 
mL/min for at least 1 h before injections were made (Note: more time was required to reach 
a stable baseline when the column was conditioned for the first time).  The temperature 
was maintained at 37 °C for the HSA columns and at 20 °C for the Con A columns, as well 
as for their respective control columns, during these experiments.  The injected analytes 
were dissolved in the same application/elution buffers as were used on each of these 
columns.  The wavelengths used for detection were 307 nm for warfarin, 316 nm for MUM 
or MUGA, and 205 nm or 220 nm for sodium nitrate. 
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In the zonal elution studies, several sample concentrations and flow rates were 
tested for use with each probe or analyte to find conditions in which the measured retention 
factors remained constant even when making small changes in these parameters.  The 
sample volumes that were used were 5 µL or 20 µL.  No significant variations in the 
retention factors were seen when using the following conditions for the zonal elution 
studies: flow rate, 0.50 mL/min; sample concentrations, 10-20 µM warfarin, 5-10 µM 
MUM or MUGA, and 2.5-5.0 µM sodium nitrate.  These conditions for providing linear 
elution conditions and results that were independent of the flow rate agreed with previous 
observations that have been made in prior studies with HSA columns [33,36,39,40]. 
The retention time for each injected solute was estimated by analyzing the 
chromatograms with PeakFit 4.12 and fitting the data by using an exponentially-modified 
Gaussian and half-Gaussian modified Gaussian (EMG+CMG) function, followed by 
determination of each peak’s first statistical moment or centroid.  All of the retention 
factors were determined for data acquired over at least three injections on the entrapped 
protein columns and control columns.  The solutes that were used as non-retained markers 
were sodium nitrate for the HSA columns and MUGA for the Con A columns.  The extra-
column void time of the system was found by measuring the elution time of the non-
retained solutes when a zero volume union was placed into the chromatographic system 
instead of the column [39]. 
The protein content of each stationary phase was measured initially by using a BCA 
protein assay [41,42].  An alternative method was also developed, as described later in this 
chapter, that involved labeling some of the protein with fluorescein, entrapping this labeled 
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protein, and then measuring the fluorescence of a slurry that was prepared with the 
entrapped and labeled protein support. 
2.3. RESULTS AND DISCUSSION 
2.3.1. Initial measurement of protein content by the BCA assay 
The protein coverage of the supports was first measured by a BCA assay.  This 
method is based on the ability of proteins to reduce Cu2+ to Cu+ in an alkaline solution (i.e., 
the biuret reaction), with the Cu+ then forming a complex with the BCA reagent to form a 
colored complex that absorbs light at 562 nm [41,42].  The initial batches of the entrapped 
HSA support that were made in this study gave only a small apparent protein content when 
measured by this assay, as well as weak retention for warfarin on a column that contained 
this support.  An increase in the reaction volume that was used during the protein 
entrapment did lead to some increase in the retention factor for warfarin, however, the 
apparent protein content of the support was still small. 
One major issue in these early experiments was that it was difficult to determine 
the protein content of the supports by the BCA protein assay.  This occurred because both 
the control support and support containing the entrapped protein gave a high response in 
this assay.  It was hypothesized that this behavior was caused by the presence of the 
hydrazide groups on the support which, like the peptide backbone of proteins, could reduce 
Cu2+ to Cu+ in the BCA assay.  The large response for the control support in this assay 
created only small differences in the final absorbances that were measured for the supports 
with entrapped proteins versus the control supports.  This, in turn, produced high variability 
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in the final results.  To resolve this issue, a search was made for another method that could 
be used to measure the protein content of these supports. 
2.3.2. Measurement of protein content in supports by fluorescence 
A method based on fluorescence was also developed and tested to estimate the 
protein content of supports that were prepared through entrapment.  This method involved 
labeling a portion of the protein with fluorescein, entrapping this protein, and then 
measuring the fluorescence of a slurry that contained the support with the entrapped and 
labeled protein.  A procedure for labeling HSA or BSA with FITC [43], was adapted for 
this work, as based on directions provided by the manufacturer of the FITC reagent [44].  
In this procedure, a solution containing 8.8 mg of the protein in 4 mL of freshly prepared 
pH 9.0, 0.10 M sodium carbonate/bicarbonate buffer was combined with 1 mL of 1 mg/mL 
FITC in the same buffer, giving a molar ratio for FITC vs. albumin of 20:1.  This mixture 
was stirred in the dark for 2 h at room temperature.   
An Econo-Pac 10DG disposable desalting column was used to separate the 
unreacted FITC from the fluorescein-protein conjugate and to carry out buffer exchange.  
In this part of the procedure, a 3 mL portion of the reaction mixture containing the excess 
FITC and the fluorescein-protein conjugate was applied to the desalting column and eluted 
with pH 7.4, 0.010 M phosphate buffered saline, according to instructions by the supplier 
of the column.  The first yellow fraction (about 4 mL, and which contained the labeled 
protein) was collected; this fraction was further purified by using an ultrafiltration tube 
with a 30 kDa MW cutoff and pH 5.0, 0.10 M potassium phosphate buffer.  The initial 
volume of the sample plus the buffer in this tube was 3 mL. The centrifugation step for this 
tube proceeded at 2.5 × 103 g and 25 °C until the volume of solution in the tube was reduced 
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to 0.5 mL.  The process of adding more buffer and centrifugation was repeated until no 
free FITC from the original solution that held the fluorescein-protein conjugate was 
detected, as based on absorbance measurements of the filtrate at 495 nm.  Three filtration 
cycles were necessary to complete this process. 
The labeling ratio for the protein conjugate (i.e., the ratio of fluorescein-to-protein, 
or F/P, in the final conjugate) was determined by making absorbance measurements at both 
280 nm (for the protein) and at 495 nm (for the fluorescein), as well as for solutions 
containing only the protein or FITC at these same wavelengths.  When BSA was used in 
this labeling method, the ratio of fluorescein-to-protein in the resulting conjugate was 
determined to be 2.37 (± 0.10) mol/mol (n = 3). 
To test for the response of the proposed fluorescence assay in the presence of silica, 
several dilutions of an FITC-BSA conjugate were placed into a slurry containing 40 mg/mL 
of diol-bonded silica in pH 7.4, 0.067 M potassium phosphate buffer.  These solutions were 
placed into a 96-well plate in 250 µL aliquots and measured for their fluorescence, using 
495 nm as the excitation wavelength and 521 nm as the emission wavelength.  As 
demonstrated in Figure 2.5 (top), a linear response with a value for r2 that was greater than 
0.98 was obtained for these results, along with a low response for the blank.  In addition, 
reproducible results were acquired for samples that contained up to 0.05 mg/mL FITC-
BSA.  To investigate the effect of settling by the support over time, measurements were 
taken after letting the slurry stand in the well plates from 1 min to 10 min.  The response 
for each slurry concentration did vary over time in this study, but the response was 
consistent when this time was kept constant for all samples and standards. 
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Figure 2.5  Typical results for a method based on fluorescence for measuring the protein 
content of supports prepared through the entrapment of BSA-FITC.  The 
upper graph shows the response that was obtained for various slurry 
concentrations of silica that contained entrapped BSA-FITC. The calibration 
plot in the bottom shows the response that was obtained when various 
amounts of FITC were added to a 0.4 mg/mL slurry of silica.  The buffer used 
in this study was pH 7.4, 0.067 M potassium phosphate buffer.  Based on this 
method, the protein content of the support containing entrapped and labeled 
BSA was estimated to be 24 (± 3) mg of BSA-FITC/g silica. 
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This assay was used to optimize the conditions for entrapping proteins such as BSA 
or HSA in silica, as accomplished by using a preparation of FITC-BSA for the entrapment 
process.  This sample was originally employed under the same conditions as were initially 
used to entrap HSA.  The resulting slurry was diluted to minimize the effects of light 
scattering by the support and to provide samples that gave measurements within the linear 
range of the assay.  Solutions containing commercial FITC-BSA or FITC-BSA that was 
prepared in-house and the control silica were used to prepare the calibration plots.  Slurries 
of the entrapped BSA-FITC that had silica concentrations ranging from 1 to 10 mg/mL 
gave signals of 5 to 60 fluorescence units and a linear response in this assay.  Slurries that 
were made with the control support or diol-bonded silica gave a background response of 
less than 2 fluorescence units over the same range of slurry concentrations.  The 
fluorescence measurements were taken within 30 s of placing the samples into the wells to 
avoid any change in the signal over time (Note: only a small effect of time on the signal 
was observed in this case because of dilute slurry concentrations that were being used). 
Determination of the entrapped protein content by fluorescence was used for 
monitoring the protein content that was obtained when using various entrapment conditions 
for both FITC-BSA and FITC-HSA (Note: the FITC-BSA was made under the same 
conditions as described for FITC-HSA).  In the final conditions that were used for these 
assays, slurries were made from the supports containing entrapped FITC-BSA or FITC-
HSA and were diluted to a slurry concentration that yielded a fluorescence signal between 
20 and 50 units.  A calibration curve was made using a slurry of the control support that 
had the same silica concentration as the sample.  The same preparation of the labelled 
protein that was used for entrapment was also used to make the standards for the calibration 
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plot.  The best-fit lines for all the resulting calibration plots had r2 values that were greater 
than 0.98.  An example of such a plot is given in the bottom of Figure 2.5.  
2.3.3. Comparison of the fluorescence assay with thermogravimetric analysis 
To further test the fluorescence assay, thermogravimetric analysis (TGA) was used 
for measuring the protein content of several samples of HSA silica that had also been 
analyzed by the BCA protein assay and the fluorescence method.  TGA is a destructive 
technique that monitors the loss in mass for a sample as the temperature of the sample is 
increased [45].  The results are given in the form of a thermogram, or a plot of mass vs. 
temperature.  This technique is quite sensitive for detecting small differences in mass with 
temperature, which makes it useful for studying changes in sample composition that occur 
as a function of temperature [46,47].  
The following conditions were found to be useful for analyzing the protein content 
of silica by TGA.  First, the sample was placed in a TGA pan and its mass was recorded 
while going from room temperature to 110 °C at 5 °C/min.  Second, this sample was held 
at 110 °C for 20 min to eliminate any traces of water that were present and to condition the 
sample; the mass was then again recorded and used as the “initial mass”.  Third, the 
temperature was increased from 110 °C to 650-850 °C at 20 °C/min while the mass was 
recorded; the result that was obtained when the mass no longer changed with the 
temperature was used as the “final mass”.  During this process, nitrogen at a flow rate of 
20 mL/min was used to purge oxygen from the analysis chamber. 
The losses in mass that were measured by TGA for the silica that contained 
entrapped proteins and for the control silica were compared.  The difference in this mass 
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should have represented the amount of protein that was entrapped in the silica, because the 
control silica had no protein but was prepared with all other reagents being the same as 
were used for the entrapment process.  An HSA silica support and a control silica support 
that were prepared by the Schiff base method were also analyzed by TGA for comparison 
of their results with those obtained for the same materials with a BCA protein assay. 
The thermogravimetric data were normalized and the percent mass loss for the 
silica samples containing protein or for the control silica supports were calculated as shown 
by Equation 2.1,   
                𝑃𝑟𝑜𝑡𝑒𝑖𝑛 % = (%𝑊𝑒1 − %𝑊𝑒2) − (%𝑊𝑐1 − %𝑊𝑐2)               (2.1) 
where %We1 and %We2 are the weight percent values for the supports that were 
prepared by entrapment (or that contained immobilized protein) at the initial temperature 
for the study (i.e., after conditioning the support at 110 °C) and at the final temperature that 
was used for the analysis, respectively.  The values of %Wc1 and %Wc2 in Equation 2.1 are 
the weight percent values that were measured at the same initial and final temperatures for 
the corresponding control support.  As this equation indicates, the difference in these 
masses should have corresponded to the amount of protein that was lost through 
combustion from the entrapped protein support during the TGA analysis.  The initial and 
final temperatures that were used in this calculation were selected so that the weight of the 
support was initially constant (i.e., after the support had been held at 110 °C), and the 
weight had reached a plateau after being heated (i.e., which usually occurred after 650 °C).  
The same temperatures were used for both the entrapped protein supports and the control 
supports.  
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Some examples of thermograms that were obtained for a control support and a 
support that contained entrapped proteins are presented in Figure 2.6.  Table 2.1 compares 
the results that were obtained by the TGA method with those for the BCA assay and the 
fluorescence method, as described in the previous section.  As can be seen in this table, 
there was a good agreement between the results that were obtained by the three methods.  
These results offered additional evidence that the fluorescence method, or TGA, could be 
used as an alternative to the BCA assay for measuring the protein content of supports that 
were prepared through entrapment. 
2.3.4. Purification of oxidized glycogen 
Various factors were considered in an attempt to increase the amount of protein that 
could be immobilized through the entrapment method.  One of these factors was the way 
in which the oxidized glycation was isolated after its oxidation with periodate and before 
its use in the entrapment method.  The oxidized glycogen that was to be used for entrapment 
was initially purified by placing a 3 mL portion of the oxidized glycogen solution onto a 
gel filtration column (i.e., an Econo-Pac 10DG disposable desalting column, 3.3 mL void 
volume, 6 kDa exclusion mass). A pH 5.0, 0.10 M potassium phosphate buffer was next 
added, as previously described for the purification of oxidized glycogen [28] and buffer 
exchange, and by following the directions provided by manufacturer of this column.  
However, this purification method appeared to give a low protein content in the entrapment 
method, as described in Section 2.3.1. 
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Figure 2.6  Typical results obtained by TGA for a support containing entrapped FITC-
BSA and a control silica.  The experimental conditions are described in the 
text. 
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Table 2.1.  Protein content of various supports prepared under the same conditions but 
that were measured by several methods. 
Immobilization 
method 
Type of protein or analysis method, and protein content 
(mg/g silica) 
HSA, 
TGA1 
BSA-FITC, 
Fluorescence2 
HSA, 
BCA assay2 
Entrapment method 22.1 23.9 (± 2.9)  
Schiff base method 35.3  30.7 (± 3.5) 
1These results were obtained for one set of samples of the protein supports (containing 
HSA) and the control supports 
2This result is based on at least three replicate samples.  
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To increase this protein content, the elution fraction from the gel filtration column 
that had the highest amount of oxidized glycogen was determined by measuring the 
absorbance at 280 nm for 1 mL portions of the collected fractions.  Fractions 2-4 (with a 
total volume of 3 mL) were found to have the highest absorbance and were used for 
entrapment.  However, no significant increase in the protein content of the entrapped 
supports was achieved under these modified conditions.  It was also observed that some 
cloudiness started to appear in the collected and oxidized glycogen fraction after about two 
days of storage at 4 °C.  Allowing this solution to sit for one week resulted in extensive 
precipitation.  It is believed that this behavior indicated that there was still some periodic 
acid left in the glycogen mixture, which continued to lead to further oxidation of the 
glycogen and its cross-linking or aggregation over time. 
To avoid these problems, an alternative method of purification for the oxidized 
glycogen was examined based on ultrafiltration.  In this method, a 4 mL portion of a 
reaction mixture that contained oxidized glycogen and periodic acid in pH 5.0, 20 mM 
sodium acetate buffer containing with 15 mM sodium chloride was placed into an 
ultrafiltration tube with a MW cutoff of 30 kDa.  This tube was centrifuged at 3 × 103 g 
and 20 °C, with pH 5.0, 0.10 M potassium phosphate buffer being added as needed.  The 
volume of the solution in the tube was filled to the 5 mL mark with this pH 5.0 buffer 
before each centrifugation cycle, and the centrifugation was continued until the solution 
volume in the tube was 2.5 mL.  This process was then repeated, following the addition of 
more pH 5.0 buffer to the tube.  During this process, some haziness was often observed in 
the oxidized glycogen solution, which may have indicated the beginning of some 
aggregation or cross-linking.  To overcome this problem, the procedure was modified by 
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carrying out three centrifugation cycles in the presence of water before the pH 5.0 buffer 
was used.  This new procedure involved at least seven centrifugation cycles, each requiring 
10 to 15 min to complete.  The purified oxidized glycogen solution that was obtained by 
this method was used within two days of preparation and did not show any cloudiness over 
at least one week of storage.  This was the type of oxidized glycogen that was used in all 
later work in this dissertation. 
2.3.5. Size fractionation of oxidized glycogen 
Glycogen is a branch-on-branch polysaccharide with a homogeneous branched 
structure that is formed by α(1→4) linked D-glucose with α(1→6) branching at about every 
8 to 12 glucose residues.  Glycogen has an average degree of branching of 7-9% and an 
average molar mass of 105 to 108 Da, with a broad size distribution in size that depends on 
the type of animal from which the glycogen was obtained [48,49].  Experiments were 
carried out to see if there were any molecules of oxidized glycogen that were too small to 
be used as capping agents for porous silica during entrapment.  Of particular interest were 
glycogen molecules that had molecular weights under 300 kDa, due to the pore size of the 
silica supports that were used in this study.   
To study the effects of the presence or absence of these smaller glycogen molecules, 
oxidized glycogen was prepared and purified by using a modified form of the ultrafiltration 
method that was described in the previous section.  This preparation was then labeled that 
same day with LyCH (i.e., a hydrazide-containing dye that can couple with compounds 
that have free aldehyde groups), according a method adapted from the literature for use 
with oxidized glycoproteins [50-52].  Briefly, a 3 mg/mL solution of LyCH was prepared 
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by dissolving this reagent in pH 6.5, 0.10 M potassium phosphate buffer and heating the 
mixture to about 50 °C.  A 17 mg portion of oxidized glycogen was purified by using an 
ultrafiltration tube with a MW cutoff of 30 kDa and was exchanged through this process 
into pH 6.5, 0.10 M potassium phosphate buffer.  The final volume of this solution was 4 
mL and its glycogen concentration was approximately 4.2 mg/mL.   
For the labeling reaction, 1 mL of the oxidized glycogen solution was mixed with 
1 mL of the LyCH solution for 2 h.  The reaction mixture was purified by gel filtration to 
remove the excess LyCH.  The same type of gel filtration column that was used initially in 
the purification of oxidized glycogen was used to remove the excess LyCH.  The fraction 
due to the first yellow band that eluted from this column contained unreacted LyCH; this 
fraction was discarded.  A second yellow band that corresponded to the labelled and 
oxidized glycogen eluted between 14 and 22 mL and was collected.  Absorbance 
measurements that were made at 428 nm on these fractions were used to monitor the elution 
process.  The LyCH-glycogen conjugate was further purified by ultrafiltration and the 
buffer was exchanged with water by using a tube with a 30 kDa cutoff and the procedure 
described in the previous section that used a series of washes with water.  The 
centrifugation cycles were stopped when no yellow color and no absorbance at 428 nm was 
detected in the filtrate, indicating that all of the excess and unreacted LyCH had been 
removed from the oxidized glycogen solution.  After this process, the yellow solution of 
the LyCH-labelled oxidized glycation was diluted to 6 mL with water, and 3 mL of this 
solution was transferred to an ultrafiltration tube with a 300 kDa cutoff.  Water was added 
to raise the volume of the solution in the tube to 6 mL, and this tube was centrifuged until 
the solution in the tube reached 2.5 mL (see   
47 
 
 
 
 
 
 
 
Figure 2.7). 
The fraction of the labeled and oxidized glycogen that passed through the 300 kDa 
cutoff membrane of the second ultrafiltration tube was found by using the absorbance 
values and the volumes of the filtrate and retentate.  The absorbance of the filtrate was 
corrected by subtracting the absorbance of the filtrate from the tube with the 30 kDa cutoff, 
which was used as a blank.  The result indicated that only 2.1% of the oxidized glycogen, 
as obtained from bovine liver, had sizes under 300 kDa.  These results showed that the 
molecular weight for most of the oxidized glycogen that was used for protein entrapment 
was greater than or equal to 300 kDa.  In related experiments, it was determined that the 
process of washing and concentrating the oxidized glycogen solutions by ultrafiltration and 
centrifugation was about three times faster on the tubes that had 300 kDa cutoff membranes 
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vs. those with a 30 kDa cutoff.  However, the 30 kDa filters were also acceptable for this 
work and were used in the following studies. 
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Figure 2.7  Ultrafiltration and centrifugation studies carried out with oxidized glycogen 
that was labelled with LyCH and that had been previously purified by gel 
filtration and ultrafiltration using a tube with a 30,000 Da MW cutoff 
(MWCO).  The image on the left show this solution before it was subjected 
to ultrafiltration and centrifugation using tubes with 300,000 Da or 30,000 
Da cutoff values; the image on the right shows the result after the 
centrifugation/ultrafiltration step that was performed for measuring the 
fraction of the glycogen that was smaller than 300,000 Da. 
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2.3.6. Optimization of protein entrapment based on measurements of protein 
content 
Several experiments were next carried out to maximize the final content of proteins 
such as HSA that could be immobilized by entrapment within silica.  This work was 
initially carried by using normal HSA and FITC-labelled BSA or HSA as model proteins.  
Modifying and changing the purification method for the oxidized glycogen from gel 
filtration to ultrafiltration, as described in the previous section, provided a 1.8-fold increase 
in the protein content that could be obtained through entrapment for FITC-BSA, as shown 
in Table 2.2.  This improvement can be explained by the multiple washing steps that were 
now used in the ultrafiltration method, which should have helped to more effectively 
eliminate periodic acid after the oxidation process.  This, in turn, should have avoided any 
further reaction of this reagent with glycogen, and prevented any aggregation or cross-
linking of the oxidized glycogen before it could react with the hydrazide-activated silica. 
Two other changes that were made in the entrapment procedure, as indicated in 
Table 2.2, involved decreasing the volume of solution that was used in the entrapment 
reaction (e.g., from 2.0 mL to 1.7 mL) and introducing a step in which the protein was 
allowed to incubate with the hydrazide-activated silica before the oxidized glycogen was 
added.  This combination of changes helped to increase the protein content by 2.5-fold 
versus the initial conditions.  Lowering the solution volume further to 1.0 mL during 
entrapment gave a 3.9-fold increase in the final protein content for HSA.  Increasing the 
protein/silica amount that was used for entrapment to 400 mg/g silica for HSA plus 
decreasing the solution volume to 0.72 mL gave an apparent increase of 3.2-fold in the 
protein content when compared to the initial reaction conditions (Note: this latter change 
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may not have been statistically significant due to the large variation in the measured protein 
content that was obtained when using the BCA assay).  Decreasing the solution volume 
further to 0.2 mL gave a 6.4- to 7.4-fold increase in protein content for the FITC-labeled 
HSA and BSA when compared to the results that were obtained with the initial reaction 
conditions for FITC-BSA. 
2.3.7. Optimization of protein entrapment based on retention factor measurements 
The conditions that could be used for entrapment were also optimized by using 
HSA as a model protein and by comparing the amount of active protein in the supports, as 
determined through retention factor measurements.  In this approach, columns that were 
prepared with each type of support, and its control support, were compared for their 
retention of warfarin, which is a drug that has well-characterized binding to HSA.  In this 
method, the retention time (tr) was measured for warfarin on both a column containing 
entrapped HSA and on a control column.  The value of the retention factor (k) on each type 
of column was then calculated according to the following expressions: 
𝑘1 =
(𝑡𝑟1−𝑡𝑚1)
(𝑡𝑚1−𝑡𝑣)
    (2.2)                      𝑘2 =
(𝑡𝑟2−𝑡𝑚2)
(𝑡𝑚2−𝑡𝑣)
         (2.3) 
𝑘 = 𝑘1 − 𝑘2      (2.4) 
where k1 and k2 are the retention factors for warfarin on the columns containing the 
entrapment protein or control support, respectively; tr1 and tr2 are the retention times for 
warfarin on these columns; tm1 and tm2 are the void times of these columns (e.g., as 
measured by using the elution times of a non-retained solute); and tv is the void time of the 
system (e.g., as measured by injecting a non-retained solute with no column present in the 
system).  
53 
 
Table 2.2.  Protein content obtained under various conditions when using the 
entrapment method 
Experiments - Initial conditions for 
entrapment and changes made in these 
conditions  
Type of protein 
Protein content 
(mg/g silica)1 
1 Initial conditions: 
Total volume,2 2.0 mL 
HSA/silica ratio, 100 mg/g 
Oxidized glycogen purified by gel filtration 
FITC-BSA 5.9 (± 0.2) 
2 Oxidized glycogen purification method 
changed from gel filtration to ultrafiltration 
FITC-BSA 10.6 (± 0.6) 
3 Total volume2 decreased from Expt. 2 to 1.7 
mL; Pre-incubation step for protein with the 
support (4 h) added to the entrapment procedure 
FITC-BSA 15 (± 2) 
4 Total volume2 changed from Expt. 3 to 1 mL 
HSA  23 (± 11) 
Con A 44 (± 15) 
5 Total volume2 decreased from Expt. 4 to 0.72 
mL; HSA/silica ratio increased to 400 mg/g 
HSA  19 (± 10) 
6 Total volume2 decreased from Expt. 5 to 0.2 
mL and HSA/silica ratio kept at 400 mg/g 
FITC-HSA 39 (± 3) 
FITC-BSA 44 (± 3) 
1These results are the average for three measurement of the protein content by using the 
fluorescence for the fluorescein-protein conjugates or the BCA assay for the unmodified 
HSA or Con A.  The numbers in parentheses represent a range of ± 1 S.D.  
2This value refers to the total volume of the solutions that were added to the support. 
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The retention factor for the control column was used to account for any non-specific 
interactions that warfarin may have had with the support.  By subtracting this value from 
the retention factor that was measured on the entrapped protein column, as indicated in 
Equation 2.2, a value for the corrected retention factor was obtained that should have been 
related only to the interactions of warfarin with the immobilized HSA.   In this study, these 
measurements were made by using 1.0 cm × 2.1 mm columns that contained the entrapped 
protein support or the control support.   
Table 2.3 shows how the corrected retention factor for warfarin changed when 
examining entrapped HSA columns that were prepared by using five sets of entrapment 
conditions.  The first column of experimental data (i.e., Experiment 1) shows the results 
that were obtained after 1) the purification method for glycogen had been changed from 
gel filtration to ultrafiltration, 2) an initial incubation time for the protein with the support 
of 4 h had been introduced, and 3) the solution volume had been reduced from 2.0 mL to 
1.0 mL.  This corresponds to the same set of conditions that were present for Experiment 
4 in Table 2.2.  
Further modifications were then made in the entrapment procedure.  Examples of 
modifications that were examined included decreasing the total reaction volume, 
increasing the concentration of the protein solution, and increasing the relative amount of 
the protein with respect to the support.  A vortex mixer was used to allow the solution 
volumes to be kept below 0.72 mL in Experiments 2-5, but this volume was decreased to 
values as low as 0.2 mL (see Experiments 4-5).   The concentration of protein that was 
used for the entrapment process increased from the reference amount of 8 mg/mL in 
Experiment 1 to a value of 100 mg/mL in Experiment 5.  The relative amount of protein 
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with respect to the support was also increased from the value of 100 mg/g in Experiment 1 
to values that ranged from 120 to 400 mg/g in the other experiments.  
Overall, these changes in the entrapment conditions allowed an increase to be 
obtained in the corrected retention factor for warfarin from a value of 3.0 in Experiment 1 
to a value of around 50 in Experiment 5.  Some trends that were noted in these experiments 
are summarized in Figure 2.8.  For instance, a 16-fold increase in the retention factor for 
warfarin was seen as the concentration of HSA that was used for entrapment was increased 
by 13-fold.  Also there was a 12.5- to 16-fold increase in this retention factor as the ratio 
of HSA-to-silica was increased by 3.3- 4.0-fold. 
In the final conditions that were selected for the entrapment method, the hydrazide-
activated silica that was produced from a 50 mg batch of diol silica was transferred to a 2 
mL vial, spun and decanted.  The remaining reaction was carried out at room temperature 
(about 20 °C) and used a programmable vortex mixer that could run unattended to combine 
and mix the reagents with the silica.  In the case of HSA, the activated support was mixed 
with 100 µL of 200 mg/mL HSA in pH 5.0, 0.10 M potassium phosphate buffer, plus 
another 100 µL of the same buffer with no protein present (Note: the additional buffer was 
used to obtain the same overall HSA concentration as was later used during the entrapment 
step).  This slurry was mixed for 4 h on the programmable vortex mixer, with the excess 
solution then being decanted from the support.  Second, 100 µL of 200 mg/mL HSA in pH 
5.0, 0.10 M potassium phosphate buffer and 100 µL of 8.5 mg/mL oxidized glycogen in 
pH 5.0, 0.10 M potassium phosphate buffer were added (total reaction volume, 0.20 mL; 
HSA concentration, 100 mg/mL; oxidized glycogen concentration, 4.25 mg/mL), and the 
slurry was mixed for another 16 h at room temperature using the vortex mixer.  To make 
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the control support, pH 5.0, 0.10 M potassium phosphate buffer was used in place of the 
protein solution.  Finally, 50 µL of a 1 mg/mL oxalic dihydrazide solution in pH 5.0, 0.10 
M potassium phosphate buffer was added to the slurry, and the mixing was continued for 
another 1 h. 
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Table 2.3.   Corrected retention factors for warfarin measured on 1.0 cm × 2.1 mm 
columns containing HSA entrapped within silica under various conditions 
Entrapment conditions 
Experiment1 
1 2 3 4 5 
Total volume (mL) 1 0.72 0.3 0.2 0.2 
Mass of silica 
(mg/mL)2 
80 88 167 250 250 
Concentration of HSA 
(mg/mL)3 
8 35 20 40 100 
Mass ratio of 
HSA/silica (mg/g)4 
100 396 120 160 400 
Concentration of 
oxidized glycogen 
(mg/mL)3 
1.2 1.3 3.0 4.2 3.75 
Mass ratio of oxidized 
glycogen/silica (mg/g)4 
15 15 18 17 15 
Retention factor5 3.0 
(± 0.6) 
15.8 
(± 1.4) 
4.0 
(± 0.9) 
9.5 
(± 2.6) 
49.9 
(± 7.9) 
1The results for experiments 1, 2 and 5 in this Table were obtained with the same 
entrapment conditions as the last three experiments for HSA that are listed in Table 2.2. 
2This value is the equivalent mass of diol-bonded silica that was present per unit of 
volume of the reaction mixture. 
3These concentrations are based on total volume of all solutions that were added. 
4These mass ratios are based on the equivalent mass of diol-bonded silica that was used. 
5These results are the averages of two or three determinations.  The value for Experiment 
5 is the average for two different batches of the entrapped HSA supports. 
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Figure 2.8  Variation in corrected retention factor (k) measured for warfarin on columns 
containing entrapped HSA that were prepared by varying the concentration 
of HSA that was used for entrapment or the relative amount of HSA versus 
the support that was used for entrapment.  The errors bars represent a range 
of ± 1 S.D. 
 
 
  
59 
 
 
 
  
60 
 
2.4. CONCLUSIONS 
Several factors were examined to maximize the amount of proteins such as BSA 
and HSA that could be immobilized onto porous silica by entrapment.  Some of the 
conditions that were modified were the purification method that was used for the oxidized 
glycogen, the concentration of protein that was used in the reaction mixture for entrapment, 
and the ratio of the protein vs. support that was used for entrapment.  Alternative ways of 
monitoring the total amount of protein or active protein in the resulting supports were also 
considered.  Examples of these methods included the use of fluorescence and 
thermogravimetric analysis.  In the following chapter, the measurement of retention factors 
with probe compounds for the entrapped proteins will be explored as another method for 
determining the protein content. 
It was found that improvements in the protein content could be achieved by 
changing several parameters.  This included altering the purification method from gel 
filtration chromatography to ultrafiltration, using a pre-incubation step for the protein with 
the support, increasing the concentration of HSA in the entrapment method, and decreasing 
the solution volume in the reaction mixture.  Changing these conditions gave up to a 7.4-
fold increase in the amount of entrapped protein that could be obtained versus the initial 
reaction conditions.  Increasing the concentration of the protein and increasing the 
protein/support mass ratio gave an even further increase in the apparent protein content, as 
represented by an increase of 16-fold in the retention factor for warfarin on entrapped HSA 
columns.  This entrapment procedure can be adapted for use with other proteins or supports 
by using methods similar to those described in this chapter.  
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CHAPTER 3.                                                                    
OPTIMIZATION OF A FLOW-BASED FORMAT FOR 
ENTRAPMENT 
3.1. INTRODUCTION 
High-performance affinity chromatography (HPAC) combines the high specificity 
of affinity chromatography with the instrumentation of HPLC to provide a fast and high 
throughput approach for biochemical separations [1-5].  Several rigid supports with high 
mechanical stability and good mass transfer properties are available for use in HPAC, such 
as porous silica beads, perfusion supports, polymer-based monoliths, and silica monoliths 
[6-11].  Chromatographic columns that contain porous silica supports and immobilized 
proteins or antibodies as affinity ligands have all been used in the past for studying 
biological interactions [12-19].   
One method that has been widely used for the immobilization of proteins to 
supports that are used in HPAC is covalent attachment.  One disadvantage of this approach 
is that it suffers from effects such as multisite attachment and steric hindrance, which may 
lead to some loss in the apparent activity of an immobilized binding agent [20-22].  In the 
previous chapter, an alternative method to covalent immobilization based on entrapment 
was optimized to produce affinity supports with high protein contents.  This technique 
offered the potential advantage of providing an immobilized protein or binding agent that 
was fully active and in a soluble form for interacting with drugs and other small analytes 
that may be applied later to the affinity column [23-26]. 
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In this chapter, an alternative method for immobilizing proteins by entrapment 
within HPLC-grade porous silica is discussed.  Ways to use this approach to further 
increase the protein content of affinity supports that are prepared through entrapment are 
also explored.  The primary method that will be examined will be based on the entrapment 
of proteins by recirculating these and the other reagents through hydrazide-activated silica 
that has previously been packed in a column.  This flow-based format should provide the 
smallest possible volume that can be occupied by the silica particles during the entrapment 
process.  It is expected that this reduced volume should promote better contact of the 
proteins with the surface and pores of the particles while the active aldehyde groups on the 
capping agent (i.e., oxidized glycogen) are reacting with hydrazide groups on the particles.  
This, in turn, should result in larger amounts of protein that can be entrapped when 
compared to the slurry-based method that was described in the previous chapter.  The on-
column method of entrapment that will be examined in this chapter should also be more 
amenable for automation than the slurry-based method.  Finally, this on-line format has the 
potential for reducing the amount of protein and reagents that are required for entrapment, 
which may make it possible to apply this technique to other types of affinity ligands. 
3.2. EXPERIMENTAL SECTION 
3.2.1. Reagents 
The human serum albumin (HSA, essentially fatty acid free, purity ≥ 96%), 
concanavalin A (Con A, type V,  lyophilized powder, purity ≥ 99 %), glycogen (from 
bovine liver, type IX; total glucose ≥ 85%, dry basis), racemic warfarin (purity ≥ 98%), R-
warfarin (purity ≥ 97%), carbamazepine (purity ≥ 98%), 4-methylumbellipheryl α-D-
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mannopyranoside (MUM, purity ≥ 96%), 4-methylumbellipheryl α-D-galactopyranoside 
(MUGA, purity ≥ 98%),  and periodic acid reagent (H5IO6, purity 99%) were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).  The Nucleosil Si-300 silica (7 m particle 
diameter, 300 Å pore size, 100 m2/g surface area) was obtained from Macherey-Nagel 
(Düren, Germany).  All other chemicals were of the purest grades available.  All buffers 
and aqueous solutions were prepared using water from a Nanopure system (Barnstead, 
Dubuque, IA, USA) or a MilliQ Advantage 10 system (EMD Millipore Corporation, 
Billerica, MA, USA).  The buffers were filtered through 0.20 μm GNWP nylon membranes 
from Millipore (Billerica, MA, USA) and were degassed by sonication under vacuum for 
at least 20 min prior to use. 
3.2.2. Apparatus 
The chromatographic system consisted of two 1200 isocratic pumps from Agilent 
(Santa Clara, CA, USA), a Series 200 UV-Vis detector and a vacuum degasser from Perkin 
Elmer (Waltham, MA, USA), a Rheodyne LabPro valve (Cotati, CA, USA) equipped with 
a 5 µL or 20 µL sample loop, and a series 1200 autosampler from Agilent.  An Isotemp 
9100 circulating water bath (Fisher Scientific, Pittsburgh, PA, USA) and a water jacket 
from Alltech (Deerfield, IL, USA) were used for temperature control of the columns.  The 
chromatographic data were collected and processed using LabView 8 software (National 
Instruments, Austin, TX, USA).  The chromatograms were analyzed using PeakFit 4.12 
(Systat Software, San Jose, CA, USA). 
Two PHD Ultra syringe pumps (Harvard Apparatus, Holliston, MA, USA) were 
used for the on-column entrapment method.  A Pack-in-a-Box system (ChromTech, Apple 
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Valley, MN, USA) was used for packing the supports into columns.  A UV-160A 
spectrophotometer (Shimadzu, Kyoto, Japan) was used for the BCA protein assay.  
3.2.3. Preparation of columns containing entrapped proteins 
Diol silica was prepared from Nucleosil 300-7 silica by following a previous 
procedure [1].  This support was then dried at 60 °C and stored in a desiccator.  Portions 
of this support (i.e., 50 mg batches of the diol silica) were further treated, as described 
previously, to produce hydrazide-activated silica [1].  Each batch of the hydrazide-
activated silica was washed with pH 7.4, 0.067 M potassium phosphate buffer and 
downward slurry packed into a 1 cm × 2.1 mm i.d. stainless steel column with the same 
type of 7.4 buffer acting as the packing solution.  In order to ensure homogeneous packing, 
a slurry of the support was made with 5 mL of the pH 7.4 buffer, which was added to the 
reservoir of the packing system after the column was attached to the bottom; this was 
followed by a step where an additional 15 mL of the 7.4 buffer was used to fill the rest of 
the reservoir.  The packing was then begun by flowing the buffer and slurry at 3.0 mL/min.  
The packing pressure and the flow were gradually increased over 10-15 min until reaching 
a maximum pressure of 3400 psi (23.4 MPa).  After 40 min, the pressure was gradually 
relieved for 10-15 min to avoid disturbing the chromatographic support in the column. 
The columns packed with hydrazide-activated silica were used for the on-column 
entrapment of proteins in the presence of solutions of the desired protein and oxidized 
glycogen.  The reagents that were used for preparing the entrapped protein supports, the 
proportions in which these reagents were combined, and the reaction times that were used 
were the same as described in Chapter 2 [25].  In this chapter, a flow-based and on-column 
entrapment approach was explored as an alternative to the previous method that was based 
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on a reaction slurry.  The conditions that were used for this modified entrapment approach 
are described in the Results and Discussion section. 
3.2.4. Chromatographic methods 
The application and elution buffer that was used for the chromatographic studies 
with HSA was pH 7.4, 0.067 M potassium phosphate.  This same buffer has been used in 
previous studies with HSA to provide physiological conditions for drug-protein binding 
studies [13,27-32].  In the work with Con A, the application/elution buffer was pH 5.0, 
0.50 M sodium acetate that contained 1 mM calcium chloride and 1 mM manganese 
chloride to ensure optimum activity for the Con A, according to conditions reported in 
previous studies [33,34].  The equilibration conditions and temperature of the 
chromatographic studies were the same as described in Chapter 2.  The wavelengths used 
for detection were 307 nm for warfarin, 285 nm for carbamazepine, 280 nm for L-
tryptophan, 316 nm for MUM and MUGA, and 205 nm or 220 nm for sodium nitrate. 
In the zonal elution studies, each analyte was dissolved in the desired application 
buffer and a sample volume of 5 µL or 20 µL was placed into the system by using an   
injection valve.  The concentrations of the analytes that were used in these experiments 
were selected so that linear elution conditions were present.  These conditions were 
determined and confirmed by making several injections at various sample concentrations 
to ensure that sample conditions were used over which the retention factor did not change 
(at the 95% confidence level) with the concentration of the injected analyte [29,32,35,36].  
The final sample concentrations that were used were 10-40 µM for each injected analyte 
or probe and 2.5-5 µM for sodium nitrate.  The flow rates that were used for measuring the 
retention factors of these compounds were between 0.2 and 0.5 mL/min, with no significant 
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difference been seen at the 95% confidence level in the results that were obtained over this 
range of flow rates.   
The retention times for each injected solute were found by carrying out a non-linear 
fit with PeakFit 4.12 and by using an exponentially-modified Gaussian and half-Gaussian 
modified Gaussian (EMG+CMG) function.  The retention time or elution time was 
estimated by using the first statistical moment of the fitted peak (i.e., the centroid).  At least 
three injections were done under each set of conditions for each solute and column.  A 
sodium nitrate solution was injected for determining the void time of each column.  The 
average retention factor and standard deviation of each solute on each entrapment column 
were calculated.  Injections of each solute on a control column were also made to correct 
for non-specific binding, as explained in Section 2.3.7.  These non-specific interactions 
accounted for less than 1% of the overall retention for warfarin and less than 2% for 
MUGA. 
3.3. RESULTS AND DISCUSSION 
3.3.1. Optimization of the on-column entrapment method 
The on-column entrapment method was initially carried out by using one syringe 
pump, where two 1 mL plastic syringes were placed and connected to columns that were 
packed with hydrazide-activated silica.  Tubing was connected to each column and directed 
to 2 mL vials.  This system is shown in Figure 3.1(a).  One column was used for the 
entrapment reaction with the desired protein and the other was used to prepare a control 
column that did not contain the protein (e.g., HSA in the initial studies with this method).  
The reagents were dissolved in pH 5.0, 0.10 M potassium phosphate buffer and recirculated 
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through the columns at 50 µL/min.  When making the entrapped protein column, 0.8 mL 
of 20 mg/mL HSA was recirculated through this column for 4 h, with the flow direction 
being changed every three minutes.  The solutions in the syringes were changed to 0.8 mL 
of a mixture of 20 mg/mL HSA and 4.2 mg/mL oxidized glycogen, and the recirculation 
was continued for 16 h.  Finally, 200 µL of a solution containing 1 mg/mL oxalic 
dihydrazide was mixed with the other reactants and the reaction was allowed to continue 
for another hour under the same recirculation conditions.  For the control column, the HSA 
solutions were replaced with pH 5.0, 0.10 M potassium phosphate buffer.  
The immobilization method with one syringe pump had some issues with bubble 
formation in the HSA solutions and the formation of a void region in the syringes, which 
was most noticeable in the syringe that was connected to the entrapped protein column.  It 
was found that atmospheric pressure was not enough to keep the solutions going through 
columns when the syringes were used to draw the solutions from the collecting vials.  The 
higher viscosity of the solution with HSA made this problem more noticeable for the 
entrapped protein column.  As a result, bubbles formed in the syringe and created a 
situation in which sometimes little or no protein solution was withdrawn by the syringe.  
To achieve a better delivery of the reagents through the column, it was necessary to 
periodically stop the delivery and refill the syringe with the solution from a collection vial.  
When the retention factor for racemic warfarin was measured for such a column, the result 
was 19 (± 2), where the value in parentheses represents one standard deviation for three 
replicate injections that were made onto the same column. 
A second column containing entrapped protein was made by using 40 mg/mL HSA, 
with most of the other conditions being kept the same as in the previous study.  The flow 
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rate was reduced to 20 µL/min in an attempt to reduce bubble formation during the 
entrapment process.  A retention factor for warfarin of 82 (± 4) was achieved when this 
second type of column was compared with its control column.  This experiment indicated 
that the use of a higher protein concentration during the entrapment process and the use of 
an improved reagent delivery system gave a significant increase in the amount of protein 
that was entrapped.  However, it was still desirable to find a way to make the entrapment 
conditions easier to control and to make this process more fully automated. 
In the next phase of this study, the columns were each connected to two syringe 
pumps that were equipped with 250 µL syringes.  These pumps were synchronized to 
recirculate a solution through the columns, with one syringe infusing a solution while the 
other was used to withdraw the same solution.  A diagram of such a system is given in 
Figure 3.1(b).  A picture of the entrapped protein columns and control columns when they 
were attached to the syringe pumps in this system is provided in Figure 3.1(c).  The volume 
of solution that was used in each syringe was 200 µL, and the syringes were used to infuse 
or withdraw 75 µL of this solution each cycle at a flow rate of 20 µL/min.  A stop time of 
1 min was included in this program between each change in direction of syringe movement 
to allow the solution to completely go through the column and relieve any pressure buildup 
before changing the direction of solution application.  The solutions in this system could 
be circulated through the columns without the formation of bubbles or foam, and the system 
could be left unattended during the entrapment reaction.  With this system, columns were 
prepared by using concentrations of HSA that ranged from 12.5 to 100 mg/mL, as were 
used to study the effect of protein concentration on the amount of protein that could be 
entrapped by this immobilization method. 
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The final entrapment procedure involved the use of the two-syringe system for 4 h 
to apply a solution that first contained only the protein dissolved in pH 5.0, 0.10 M 
potassium phosphate buffer; this was followed by the application of a mixture of the protein 
and 4.2 mg/mL of oxidized glycogen in the same buffer for 16 h.  Finally, a portion of 200 
µL of 1 mg/mL oxalic dihydrazide in the same buffer was added to the reaction mixture 
and the solution delivery was continued for another 2 h at room temperature.  A control 
column was made under the same conditions but with the solution of HSA being replaced 
with an equal volume of pH 5.0, 0.10 M potassium phosphate buffer.   
Immediately after this reaction was finished, the column was connected to an HPLC 
pump and pH 7.4, 0.067 M potassium phosphate buffer was applied at 0.5 mL/min for 1 h 
to wash away the excess reactants (e.g., any unreacted oxidized glycogen or oxalic 
dihydrazide, and any remaining non-entrapped HSA). 
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Figure 3.1  (a) Diagram of the on-column entrapment method with one syringe pump or 
(b) two syringe pumps, and (c) an image of the on-column entrapment system 
with two syringe pumps.  The concentrations of protein and oxidized glycogen 
in pH 5.0, 0.10 M phosphate buffer, the volume of the solutions that were used 
and the flow rate are all indicated.  Other entrapment conditions are given in 
the text.  
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The dual-syringe entrapment system was used to make several columns that 
contained entrapped HSA or Con A to study the effects of the protein concentration in the 
reaction mixture on the protein content of the resulting support.  Examples of some 
chromatograms and retention factors that were obtained for R/S-warfarin on columns that 
were made by entrapment and using various concentrations of HSA are shown in Figure 
3.2.  The results for a column that was made by using the slurry entrapment method and 
100 mg/mL of HSA are also included in this figure for comparison.  For these HSA 
columns, a 1.7-fold increase in the retention factor for R/S-warfarin occurred when going 
from conditions that used 12.5 to 25 mg/mL HSA during the entrapment process.  An 
increase of 6.3% was seen in going from using 25 to 50 mg/mL HSA during entrapment.  
These results indicated that an on-column entrapment method using 25 mg/mL HSA was 
probably the most efficient and cost effective approach for entrapping this protein under 
this given set of conditions. 
These data were also used to compare the results obtained with the slurry method 
vs. entrapment.  In the slurry method, a 0.4 mL portion of 100 mg/mL HSA was used to 
make the column, or a total of 40 mg protein.  The on-column method only needed 0.4 mL 
of 25 mg/mL HSA to make a column of the same size, or the equivalent of 10 mg protein, 
and the retention factor that was obtained for warfarin increased by 1.5-fold (or was about 
50% higher).  Thus, the on-column method based on 25 mg/mL HSA was also a more 
efficient and cost-effective approach for entrapment than the slurry method under this set 
of conditions.  
Some chromatograms and retention results that were obtained for Con A columns 
that were prepared by the on-column method and slurry method are shown in Figure 3.3.  
81 
 
 
 
 
 
 
 
 
Figure 3.2 Chromatograms and retention factors obtained for R/S-warfarin on columns 
containing entrapped HSA and made by the slurry method or the on-column 
method and using various protein concentrations in the reaction mixture.  
Conditions: sample, 40 µM R/S-warfarin; column size, 1.0 cm × 2.1 mm 
i.d.; flow rate, 0.50 mL/min; temperature, 37 ºC.  The values in parentheses 
represent a range of ± 1 S.D. (n = 3-4). 
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Figure 3.3 Chromatograms and retention factors obtained for MUM on columns 
containing entrapped Con A that were prepared by various methods and 
reaction conditions.  The bottom chromatogram shows the results for 
MUGA, which does not bind to Con A, and which was used to measure the 
void time of the Con A columns.  Conditions: samples, 10 µM MUM or 10 
µM MUGA; column size, 1.0 cm × 2.1 mm I.D.; flow rate, 0.50 mL/min; 
temperature, 20 ºC.  The values in parentheses represent a range of ± 1 S.D. 
(n = 3).  
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The solubility of Con A limited the concentrations that could be used with the 
protein for the entrapment process, but an increase of over two-fold in the retention factor 
for MUM was seen when going from columns that were made using 1 mg/mL to 5 mg/mL 
Con A (Note: at this later concentration, some of the Con A started to precipitate, and it 
was necessary to filter this solution before using it for entrapment).  The column that was 
prepared by using 1 mg/mL Con A in the on-column entrapment method gave a retention 
factor for MUM that was 1.2-fold higher than what was seen for the column that was made 
using the same concentration of Con A in the slurry entrapment method.  The column that 
was made using 5 mg/mL Con A for on-column entrapment gave 2.6-fold higher retention 
for MUM than the column that was made by the slurry method and using 1 mg/mL Con A.   
3.3.2. Estimation of protein content following on-column entrapment 
In the on-column method, the entrapment is performed directly on the column and 
it is not possible to analyze the protein directly on the support by means such as absorbance, 
fluorescence or a standard protein assay.  However, it could be possible to estimate the 
content of the active protein in the resulting column by conducting zonal elution 
experiments in which solutes are injected that have known interactions and association 
equilibrium constants (Ka) for these proteins.  This latter approach was employed in this 
study. 
One feature that makes the entrapment technique suitable to this type of assay is 
the fact that the protein is immobilized without covalent linkage to the support [16,25].  As 
a result, the active sites of the protein should be fully active and available to an injected 
probe that is able to enter the support and bind to these sites.  Under these conditions, the 
retention factor that is measured for the injected probe (k) can be related to the strength of 
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the probe-protein interaction and the amount of protein in the column through the following 
relationship [16,24,37]. 
       𝑘 = (𝑛1𝐾𝑎1 + 𝑛2𝐾𝑎2 + ⋯ 𝑛𝑛𝐾𝑎𝑛)𝑚𝐿𝑡𝑜𝑡𝑎𝑙/𝑉𝑚                             (3.1)  
were mLtotal represents the total moles of binding sites for the probe in the column, and Vm 
is the column void volume.  The term in parentheses is a number-weighted sum of the 
association equilibrium constants for all of the binding sites that are involved in the probe-
protein interaction, where ni is the relative number of moles of binding site i per mole of 
protein, and Kai is the association equilibrium constant of the probe at binding site i.  This 
equation also assumes that all the binding sites for the probe are independent of each 
another [16,24,37]. 
For the case of probe compounds that have only a single binding site on a protein 
(e.g., as is the case for warfarin and carbamazepine with HSA) [16,29], Equation 3.1 can 
be rewritten in the form shown in Equation 3.2 [16]. 
𝑘 = 𝐾𝑎
𝑚𝐿𝑡𝑜𝑡𝑎𝑙
𝑉𝑚
                                              (3.2) 
In this case n = 1 for the probe (e.g., warfarin), and the ratio mLtotal/Vm represents 
the total concentration of protein that is immobilized or entrapped in the column [12,13,16].  
If the retention factor is also corrected for any non-specific binding that may be occurring 
with the support, this corrected value can be used with Equation 3.2 to estimate the 
concentration or total moles of protein in the column. 
The protein contents for columns containing entrapped HSA were estimated by 
using carbamazepine or warfarin as the injected probes.  The following association 
equilibrium constants have been previously reported for the interactions of these drugs with 
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HSA at pH 7.4 and 37ºC: carbamazepine, 5.4 (± 0.2) × 103 M-1; R-warfarin, 2.1 (± 0.2) × 
105 M-1; and racemic warfarin, 2.3 (± 0.4) × 105 M-1, where this value is the average of the 
values for R- and S-warfarin [29,30,32].  The retention measurements that were made for 
all of these drugs were also carried out at pH 7.4 and 37ºC, along with a flow rate of 0.2 or 
0.5 mL/min.  Table 3.1 shows the corrected retention factors that were obtained with these 
probes on columns that were made by using on-column entrapment method and various 
concentrations of HSA.  The protein contents that were estimated from these results are 
shown in Table 3.2.   
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Table 3.1.  Corrected retention factors measured for several probe compounds that were 
injected onto HSA columns that were prepared by the on-column entrapment method and 
using various concentrations of HSA in the reaction mixture1  
Type of entrapment method 
and HSA concentration 
Corrected retention factor, k 
Carbamazepine     R-Warfarin    R/S-Warfarin 
Slurry method, 100 mg/mL 
HSA  
0.95 (± 0.12) 39.5 (± 4.4) 37.6  (± 5.2) 
On-column method, 12.5 
mg/mL HSA 
1.42 (± 0.20) 45.1 (± 7.0) 42.4 (± 1.0) 
On-column method, 25 mg/mL 
HSA 
1.65 (± 0.20) 61.1 (± 4.4) 68.2 (± 3.8) 
On-column method, 40 mg/mL 
HSA2 
1.98 (± 0.24) 69.0 (± 5.7) 65.2 (± 2.9) 
On-column method, 50 mg/mL 
HSA 
1.91 (± 0.11) 73.9 (± 4.5) 75.6 (± 3.5) 
On-column method, 100 
mg/mL HSA 
5.75 (± 1.01) 196.1 (± 5.4) 227.8 (± 5.4) 
1The results for an HSA column that was prepared by the slurry method and using 100 mg/mL HSA 
is included in this table for reference.  All of the retention factors in this table were measured at 
0.5 mL/min and 37 °C.  The numbers in parentheses represent a range of ± 1 S.D., as obtained for 
at least two or three injections per column; the only exception was for R/S-warfarin, in which two 
or three columns were used and the value that is given is the combined average of the retention 
factors for these columns. 
2This type of support was prepared by using only one syringe pump. 
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Table 3.2.  Protein content measured by using the retention factors for several probe 
compounds that were injected onto HSA columns that were prepared by the on-column 
entrapment method and using various concentrations of HSA in the reaction mixture1  
Type of entrapment 
method and HSA 
concentration 
 
Protein content (mg/g silica)1 
Carbamazepine R-Warfarin R/S-Warfarin Average 
Slurry method, 100 
mg/mL HSA  
20.7 (± 5.7) 22.1 (± 6.3) 19.2 (± 6.3) 20.7 (± 3.5) 
On-column method, 
12.5 mg/mL HSA  
23.5 (± 7.1) 19.2 (± 6.2) 20.9 (± 6.4) 21.2 (± 3.8) 
On-column method, 
25 mg/mL HSA  
34.0 (± 8.9) 32.3 (± 8.4) 32.9 (± 9.7) 33.1 (± 5.2) 
On-column method, 
40 mg/mL HSA  
39.3 (± 10.4) 35.2 (± 9.4) 30.4 (± 9.0) 35.0 (± 5.6) 
On-column method, 
50 mg/mL HSA  
45.9 (± 10.7) 34.3 (± 8.8) 40.0 (± 11.5) 40.1 (± 6.0) 
On-column method, 
100 mg/mL HSA  
126 (± 37) 114 (± 28) 121 (± 34) 120 (± 19) 
 
1The conditions are the same as in Table 3.1.  The numbers in parentheses represent a 
range of ± 1 S.D., as obtained for at least three injections per column.  The protein content 
was calculated by using molar mass of 66.4 kDa for HSA, the volume of the column, and 
a packing density for silica of 0.45 g/cm3.  A 1:1 binding model was used along with the 
following association equilibrium constants: carbamazepine: 5.4 (± 0.2) × 103 M-1 [29], R-
warfarin, 2.1 (± 0.2) × 105 M-1; racemic warfarin, 2.3 (± 0.4) × 105 M-1, where this last value 
is the average of the values for R- and S-warfarin) [32].  
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The protein content that was obtained through this process for the HSA column that 
was made by the slurry entrapment method was compared to the result that was estimated 
for the same type of support when using a protein assay.  In this case, the protein content 
was also estimated by using fluorescence measurements and a support that had been 
prepared under the same conditions by using fluorescein-labeled HSA.  The reference 
method gave a protein content for this support that was equal to 20.1 (± 1.1) mg/g of silica.  
This value was statistically equivalent to the values that were estimated in Table 3.2 when 
using the injected probes and their measured retention factors. 
It can be observed in Tables 3.1 and 3.2 that the retention factors and calculated 
protein contents gave similar trends in the results that were obtained for carbamazepine, R-
warfarin and R/S-warfarin.  The use of even 12.5 mg/mL HSA in the on-column entrapment 
method gave a similar protein content to what was obtained when using 100 mg/mL HSA 
in the slurry entrapment method.  Using a higher concentration of HSA in the on-column 
entrapment method tended to give an increase in the measured retention factors and 
estimated protein content of the final column.  The column that was made using 100 mg/mL 
HSA for on-column entrapment gave the highest overall retention and protein content.  The 
protein content of this column was about six-fold higher than the protein content that was 
obtained by the slurry entrapment method when using the same concentration of HSA for 
entrapment.  Approximately the same increase was seen in going from the use of 12.5 to 
100 mg/mL HSA for on-column entrapment. 
Although the three types of probe compounds gave good agreement in the protein 
contents that they provided for these columns, there were advantages and disadvantages to 
the use of each type of probe.  The analysis time for the elution of carbamazepine was 
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shorter than for warfarin because the affinity of this drug for HSA was also weaker.  This 
made this probe useful for obtaining a fast estimate of the protein content; however, this 
feature also made this probe more difficult to use than warfarin for examining the protein 
content of small columns.  R-Warfarin gave sharper elution profiles than racemic warfarin, 
since this peak was due to only a single enantiomer rather than the result of two overlapping 
peaks for two enantiomers.  However, R-warfarin was also much more expensive than 
racemic warfarin and more difficult to obtain. 
3.3.3. Column stability and comparison with previous HSA columns 
Table 3.3 compares the retention factors that were measured in this study for 
warfarin on the columns that were prepared by entrapment vs. results obtained with 
previous HSA columns that have been used with this probe and that have been prepared by 
covalent immobilization methods.  It can be seen that the retention factors obtained by the 
entrapment method were similar to or higher than the highest retention factors that have 
been obtained in prior work with HSA that has been covalently immobilized to silica by 
the Schiff base method.  This difference was particularly true in the case where the retention 
factors were compared for the on-column entrapment method that used up to 100 mg/mL 
HSA for entrapment. 
The data in Table 3.3 for the entrapment method also provide some information on 
the stability and reproducibility of the columns that were prepared by this approach.  For 
instance, the two top entries in Table 3.3 provide the range of retention factors that were 
obtained over the course of about one and a half years for columns that were made by the 
slurry entrapment method and the on-column entrapment method.  These results indicate 
that both entrapment methods were able to provide HSA supports that had good activity 
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for extended periods of time when used under the storage and application conditions that 
were employed in this study.  These two types of columns were each stored at 4 °C when 
not in use and were used for multiple injections of various probes, with typical lifetimes of 
over 150 h of use at a flow rate of 0.5 mL/min. 
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Table 3.3.  Comparison of retention factors measured for warfarin with columns 
containing immobilized HSA that were prepared by entrapment or through covalent 
immobilization 
 
  
Experiment/ 
Type of warfarin 
Retention 
factor, k 
Method and conditions [Refs.] 
1) Racemic   38-511 
Slurry entrapment method using 100 mg/mL HSA and 
porous silica.  Column size: 1 cm × 2.1 mm. Mobile phase: 
pH 7.4, 0.067 M potassium phosphate buffer.  
Temperature: 37 °C. 
2) Racemic   70-822 
On-column entrapment method using 50 mg/mL of HSA 
and porous silica.  Column size: 1 cm × 2.1 mm.  Mobile 
phase: pH 7.4, 0.067 M potassium phosphate buffer.  
Temperature: 37 °C 
3) R-Warfarin 74 (± 4)3 Same conditions as the previous experiment 
4) Racemic 191-2362 
100 mg/mL of HSA, the other conditions were the  same  
as the previous experiment 
5) R-Warfarin 196-2242 Same conditions as the previous experiment 
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Table 3.3.  (Continued) 
1This range of results was obtained over 1.5 years using the same column. 
2This range of results was obtained over 1.5 years from two columns. 
3These results were obtained over three injections on the same day and on one column. 
4The value was calculated from a point in a graph, so no standard error is available. 
52-Propanol and octanoic acid were used in this case as mobile phase modifiers or 
competing agents to adjust and lower the retention factors for the injected analytes. 
6These are average retention factors at flow rates from 0.1 to 5 mL/min.   All other 
experiments were performed at 0.5 mL/min. 
  
Experiment/ 
Type of warfarin 
Retention 
factor, k 
Method and conditions [Refs.] 
R-Warfarin 2.3 (± 0.2) Schiff base method.  Column size: 5 cm × 2.1 mm.  Mobile 
phase: pH 7.4, 0.067 M potassium phosphate buffer.  
Room temperature [15] 
S-Warfarin 98 (± 1) 
R-Warfarin 39
4 
Schiff base method.  Column size: 5 cm × 2.1 or 4.6 mm.  
Mobile phase: pH 7.4, 0.067 M potassium phosphate 
buffer.  Temperature:  37 ° C [16] 
R-Warfarin 12.8 (± 0.3)
5 Schiff base method.  Column size: 5 cm × 4.6 mm.  Mobile 
phase: pH 7.4, 0.067 M potassium phosphate buffer, 
containing 5% 2-propanol and 1 mM octanoic acid.  
Temperature: 25 °C  [31] 
S-Warfarin 26.8 (± 0.4)
5 
R-Warfarin 
82 (± 4)6 Schiff base method.  Column size: 2.0, 0.5 or 0.1 cm 
length, respectively, 2.1 mm I.D.  Mobile phase: pH 7.4, 
0.067 M potassium phosphate buffer. Temperature: 37 °C 
[31] 
57 (± 6)6 
38 (± 8)6 
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3.4. CONCLUSIONS 
Several factors were examined for maximizing the amount of HSA or Con A that 
could be immobilized within porous silica by the on-column entrapment method.  These 
factors included the use of one or two syringe pumps, the flow rate that was used for the 
entrapment process, and the protein concentration that was employed.  A technique for 
determining the protein content of HSA supports that were made by the on-column 
approach was also developed, which was based on the use of injected probes such as 
warfarin and carbamazepine.  It was found in the use of on-column entrapment for HSA 
that the final protein content could be increased by at least six-fold versus what has been 
observed for columns that were made with the slurry method of entrapment.  The 
entrapment of Con A also increased by almost three-fold with the use of the on-column 
method. 
One reason for the higher levels of protein that were obtained in the on-column 
method is the reduced volume of the reaction slurry that was occupied by the packed 
support.  In the on-column method, only the void volume of the column was available for 
the entrapment reaction, which probably led to an increased chance for the protein getting 
entrapped when the oxidized glycogen molecules reacted with hydrazide groups on the 
support.  The use of flow to pass these reagents through the support may also have 
increased the contact of the protein with the pores during this process.   
This on-column entrapment approach can be adapted for use with other proteins or 
supports.  The protein content that can be obtained by this method should be advantageous 
in future work with microcolumns or microfluidic systems or for any application of HPAC 
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in which relative strong binding or good retention is needed in small devices or 
miniaturized systems. 
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CHAPTER 4.                                                                                 
RAPID ANALYSIS OF DRUG PROTEIN BINDING BASED ON 
COLUMNS PREPARED BY ENTRAPMENT 
4.1. INTRODUCTION 
It is important to know the activity and fate of pharmaceutical agents in the body.  
When a drug enters the circulatory system, it may undergo interactions with proteins that 
are found in blood, such as human serum albumin (HSA), α1-acid glycoprotein (AGP) and 
lipoproteins.  These interactions can be described by using a parameter such as the 
association equilibrium constant (Ka) of the drug-protein complex.  These drug-protein 
interactions are often strong and significant, with approximately 43% of the 1500 most 
common drugs having at least 90% binding to serum proteins.  As a result, these 
interactions can have a large impact on the absorption, distribution, metabolism and 
excretion (ADME) of a drug in the human body [1]. 
Because of the potential impact of these interactions, it is important to conduct 
drug-protein binding studies on pharmaceutical agents to help determine their dosages and 
the frequency at which these drugs should be taken [2].  Binding studies that are conducted 
in vitro may give general information for a particular drug and its interactions, while in 
vivo studies can potentially provide specific information that is more tailored to an 
individual patient’s needs, as can be used for personalized medicine [3]. 
Human serum albumin (HSA) is a transport protein in the circulatory system that 
can bind to many endogenous and exogenous compounds.  HSA is the most abundant 
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protein in human plasma, where it is found at concentrations ranging from 30–50 g/L 
(0.53–0.75 mM).  The high concentration of HSA accounts for approximately 60% of the 
total protein content in serum and gives this protein the ability to greatly influence the 
pharmacokinetics and activity of many common drugs [4-6].  HSA plays a key role in the 
reversible binding and transport of drugs, metabolites, and various endogenous ligands 
such as fatty acids.  In addition, HSA can increase the solubility of lipophilic drugs, 
sequester toxins, and act as an important antioxidant in plasma [7,8].  
There are two major binding sites for drugs on HSA, which are located in 
subdomains IIA and IIIA of this protein.  These sites are often referred to as Sudlow sites 
I and II after Gillian Sudlow, who proposed their existence in 1975 [9,10].  Sudlow site I, 
which is also known as the warfarin-azapropazone site, binds to bulky heterocyclic anions 
such as warfarin and salicylate.  Sudlow site II, or the indole-benzodiazepine site, binds 
primarily to aromatic carboxylic acids like ibuprofen and L-tryptophan.  At least two minor 
binding sites for drugs HSA have also been proposed for compounds such as digitoxin and 
tamoxifen (i.e., the digitoxin site and tamoxifen site) [11,12]. 
Diabetes is a metabolic disease that can be described as a group of disorders that 
result from insulin deficiency and/or insulin resistance.  Insulin is a hormone produced in 
the beta cells of the islets of Langerhans of the pancreas and is responsible for the regulation 
of glucose in the circulation.  The presence of either insulin deficiency or insulin resistance 
in diabetes produces abnormally high levels of glucose in blood and results in a condition 
known as hyperglycemia [13,14].  Diabetes is a major cause of morbidity and mortality, 
and its global prevalence is growing rapidly [15].  The number of people worldwide who 
have diabetes is estimated to be around 366 million, and this figure is projected to rise to 
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552 million by 2030.  In the United States, it is estimated that 26 million people now live 
with this disease [3,16].  The high blood glucose concentrations that are seen in diabetes 
can lead to a number of detrimental health effects, ranging from an increased risk of heart 
disease and stroke to kidney disease, blindness, and lower limb amputations [13].   
There are two types of diabetes: type 1 diabetes, which is also known as immune-
mediated, insulin-dependent or juvenile-onset diabetes; and type 2 diabetes, which is also 
called non-insulin dependent or adult-onset diabetes.  In type 1 diabetes, the body’s 
immune system attacks the pancreatic beta cells that produce insulin.  Type 2 diabetes is 
caused by an inadequate cellular response to insulin in organs or tissue (e.g., adipose cells).  
This later type of diabetes is the most common, accounting for 90 to 95% of the individuals 
with this disease, and is strongly related to obesity, age, and a family history of this disease 
[3,16]. 
Many of the long term complications of diabetes, such as heart disease and nerve 
damage, are associated with the non-enzymatic glycation of proteins that occurs in the 
presence of sustained high levels of glucose in blood [14,17].  The process of protein 
glycation is shown in Figure 4.1.  Glycation starts when a reducing sugar such as glucose 
undergoes a nucleophilic attack onto a primary amine group on a protein to form a 
reversible Schiff base.  This intermediate can then slowly rearrange to form a more stable 
Amadori product [14,17,18].  Oxidation and rearrangement of the Amadori products or 
free sugars can also generate reactive α-oxaloaldehydes that react with both lysines and 
arginines on proteins to form advanced glycation end-products (AGEs) [14,18]. 
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Figure 4.1 General reactions involved in the glycation of a protein such as human serum 
albumin (HSA).  This figure is adapted with permission from Ref. [14]. 
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In recent years, it has been found that the glycation of HSA may affect its binding 
to solutes such as many drugs.  Sulfonylureas, which are often used to treat type 2 diabetes, 
are one group of drugs that have been found to be affected by this glycation process.  These 
drugs are highly bound to serum proteins, and especially to HSA [14,19-24].  Binding 
studies based on high-performance affinity chromatography (HPAC) have found that 
glycation can affect the equilibrium constants of sulfonylurea drugs with HSA and that the 
extent of this change is affected by both the degree of protein glycation and the specific 
drug that is being examined [3,14,19-23,25]. 
This chapter deals with the application of a new and rapid approach for performing 
drug-protein binding studies by using preparations of entrapped proteins and zonal elution 
experiments.  The use of columns that contained entrapped proteins should allow the 
determination of binding constants from simple retention measurements because the 
immobilized protein in such a column remains in a soluble state and is fully active.  This 
feature should allow for a simplification in the measurements that are needed for 
determining binding constants through chromatographic methods, because there is no need 
to perform additional independent experiments to obtain the amount of active ligand that 
is present in the column [19].   
This technique will be tested and applied to studying the effects of glycation on 
HSA with regards to the binding of this protein with three sulfonylurea drugs: 
acetohexamide, tolbutamide and gliclazide.  The results will be used to see how HPAC and 
columns made by entrapment can be used to study the effects of glycation on drug-protein 
binding and to determine the binding constants of a drug with a protein through a simple 
set of experiments and series of sample injections.  
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4.2. EXPERIMENTAL SECTION 
4.2.1. Materials 
The HSA (essentially fatty acid free, purity ≥ 96%), glycogen (bovine liver, type 
IX; total glucose ≥ 85%, dry basis), racemic warfarin (purity ≥ 98%), R-warfarin (purity ≥ 
97%), L-tryptophan (purity ≥ 98%) and periodic acid reagent (H5IO6, purity 99%) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  Nucleosil Si-300 silica (7 m 
particle diameter, 300 Å pore size, 100 m2/g surface area) was obtained from Macherey-
Nagel (Düren, Germany).  The in vitro samples of glycated HSA were purified through the 
use of Econo-Pac 10DG desalting columns from Bio-Rad Laboratories (Hercules, CA, 
USA) and Slide-A-Lyzer digest 7K dialysis cassettes (7 kDa MW cutoff; 0.5-3, 3-12 or 12-
30 mL sample volumes) from ThermoScientific (Rockford, IL, USA).  All other chemicals 
were of the purest grades available.  All buffers and aqueous solutions were prepared using 
water from a Milli-Q Advantage 10 system (EMD Millipore Corporation, Billerica, MA, 
USA).  The buffers were filtered through 0.20 μm GNWP nylon membranes from Millipore 
(Billerica, MA, USA) and were degassed by sonication under vacuum for at least 20 min 
prior to use.  A fructosamine assay kit, obtained from Diazyme Laboratories (San Diego, 
CA, USA), was used to measure the glycation levels of the in vitro glycated HSA. 
4.2.2. Apparatus 
The chromatographic system that was used in the zonal elution studies consisted of 
a DG-2080 degasser, two PU-2080 pumps, an AS-2057 autosampler, a CO-2060 column 
oven, and a UV-2075 absorbance detector from Jasco (Tokyo, Japan), plus a Rheodyne 
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LabPro six-port valve (Cotati, CA, USA).  LC Net and ChromNav from Jasco (Tokyo, 
Japan) were used to control the chromatographic system and to collect the data. 
For the frontal analysis studies, two 1200 isocratic pumps and a 1200 autosampler 
from Agilent (Santa Clara, CA, USA) were used, along with a Series 200 UV-Vis detector 
and a vacuum degasser from Perkin Elmer (Waltham, MA, USA).  A Rheodyne LabPro 
valve and an Isotemp 9100 circulating water bath (Fisher Scientific, Pittsburgh, PA, USA) 
with a water jacket from Alltech (Deerfield, IL, USA) were used for temperature control 
of the columns.  The chromatographic data in this case were collected and processed using 
LabView 8 software (National Instruments, Austin, TX, USA).  
The results for the zonal elution and frontal analysis experiments were analyzed by 
using PeakFit 4.12 (Systat Software, San Jose, CA, USA).  Regression analysis of the 
frontal analysis data was performed with Origin 2015 (OriginLab, Northampton, MA, 
USA).  The calculation of retention factors and binding constants was performed with 
Microsoft Excel 2013 (Microsoft, Redmond, WA, USA). 
A Pack-in-a-Box system (ChromTech, Apple Valley, MN, USA) was used for 
packing the supports into the columns.  Two PHD Ultra syringe pumps (Harvard 
Apparatus, Holliston, MA, USA) were used for the on-column entrapment method.  A 
Jasco V-630 UV/VIS spectrophotometer (Jasco, Kyoto, Japan) equipped with temperature 
control for the cuvette holder was used for taking absorbance readings during the 
fructosamine assay. 
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4.2.3. Preparation of in vitro glycated HSA 
Three samples of in vitro glycated HSA were prepared at physiological 
concentrations of HSA and glucose, as described previously [26-28].  These samples were 
representative of glycation levels that are found in patients with prediabetes, confirmed 
diabetes, and advanced diabetes, and will be referred to in this chapter as “gHSA1”, 
“gHSA2” and “gHSA3”, respectively.  To prevent bacterial growth during the glycation 
process, all materials (e.g., glassware and spatulas) were first sterilized in an autoclave.  A 
pH 7.4, 0.20 M potassium phosphate buffer containing 1 mM sodium azide was prepared 
for use in this procedure.  This buffer was also sterilized in an autoclave to prevent bacterial 
growth. 
The in vitro glycated HSA was prepared by dissolving 840 mg of normal HSA into 
a solution that contained 5 mM, 15 mM or 30 mM glucose (i.e., for the preparation of 
gHSA1, gHSA2 or gHSA3, respectively) in sterile pH 7.4, 0.20 M phosphate buffer.  The 
final concentration of HSA in these solutions was 42 mg/mL, or 0.63 mM.  This 
concentration of HSA was within the typical range (35–50 g/L) that is found in human 
serum under normal physiological conditions.  These protein/glucose mixtures were 
incubated for five weeks at 37 °C to produce glycated HSA.  The proteins in these samples 
were later purified through the use of size exclusion columns and pH 7.4, 0.067 M 
potassium phosphate buffer to remove the excess glucose.  The collected protein fractions 
were further dialyzed three times, using sterile dialysis cassettes and against a volume of 
water that was 200-500 times the volume of the protein solution [26].  The final protein 
solutions were lyophilized and stored at -80 °C until further use. 
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Portions of the in vitro glycated HSA samples were analyzed in triplicate by using 
a fructosamine assay to determine their glycation levels, as described previously 
[26,29,30].  The measured glycation levels were 0.27 (± 0.01), 2.01 (± 0.05) and 4.13 (± 
0.08) mol hexose/mol HSA for gHSA1, gHSA2 and gHSA3, respectively.  These levels of 
glycation were comparable to those obtained in prior studies that used a similar approach 
to prepare in vitro glycated HSA [26,30]. 
4.2.4. Support preparation 
Diol-bonded silica was prepared from Nucleosil 300-7 silica, as described 
previously, followed by the drying of this support and its storage for future use.  Hydrazide-
activated silica was prepared from the diol-bonded silica also according to a procedure that 
has been described in the literature [31].  The support size of 7 µm and the pore size of 300 
Å that were chosen for these supports have previously been found to be optimal for the 
entrapment of HSA and proteins with comparable sizes [32]. 
An amount of hydrazide-activated silica that was equivalent to an initial amount of 
50 mg of diol-bonded silica was washed with pH 7.4, 0.067 M potassium phosphate buffer 
and downward slurry packed into 1.0 cm × 2.1 mm stainless steel columns by using pH 
7.4, 0.067 M potassium phosphate buffer as the packing solution, as indicated in Section 
3.2.3 of this dissertation.  The columns that were packed with the hydrazide-activated silica 
were used for the on-column entrapment of normal HSA or HSA with various levels of 
glycation. 
The conditions used for on-column entrapment were the same as the final 
conditions of on-column entrapment that were described in Section 3.3.1 of this 
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dissertation.  A solution containing 50 mg/mL of the normal HSA or glycated HSA in pH 
5.0, 0.10 M potassium phosphate buffer was circulated through the column at 20 µL/min 
for 4 h.  This was followed by the application of a solution over 16 h that contained a 
mixture of the normal HSA or glycated HSA at 50 mg/mL and oxidized glycogen at 4.2 
mg/mL in the same phosphate buffer.  Finally, 200 µL of 1 mg/mL of oxalic dihydrazide 
in the same buffer was added to the reaction mixture, and the circulation of this solution 
through the column was continued for two more hours.  A control column was made under 
the same conditions but with the solutions of HSA being replaced with an equal volume of 
pH 5.0, 0.10 M potassium phosphate buffer.  All of the columns were washed by flowing 
pH 7.4, 0.067 M potassium phosphate buffer through them at 0.5 mL/min for 1 h or until 
a stable baseline response was reached for these columns. 
4.2.5. Chromatographic studies 
Stock solutions of the sulfonylurea drugs (i.e., acetohexamide, tolbutamide and 
gliclazide) were prepared in pH 7.4, 0.067 M potassium phosphate buffer at a typical 
concentration of 100 µM.  The stock solutions of the site-specific probes were also prepared 
in this buffer and had typical concentrations of 100 µM for warfarin and 1.3 mM for L-
tryptophan.  The acetohexamide, tolbutamide and gliclazide solutions were used within 
one week of preparation.  The warfarin solutions were used within one week, and L-
tryptophan solutions were used within two days of preparation.  It has been demonstrated 
in previous studies that similar solutions of these drugs and solutes are stable over for these 
given periods of time.  
The mobile phases that were used in the competition studies with the site-specific 
probes were prepared at concentrations that were typically 1 mM for L-tryptophan and 40 
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µM for warfarin, as made by diluting the stock solutions for these probes with pH 7.4, 
0.067 M potassium phosphate buffer.  The injected samples for these experiments were 
prepared by using the stock solutions for the sulfonylurea drugs, warfarin or L-tryptophan 
and the pH 7.4, 0.067 M potassium phosphate buffer.  The concentrations of the 
sulfonylurea drugs ranged from 20 µM to 40 µM.  Additional experiments were performed 
by using 10 µM L-tryptophan or 20 µM warfarin in the same pH 7.4 buffer, as used for 
determining the retention factors and protein content of the normal HSA and glycated HSA 
columns.  It has been shown in previous work that the sample concentrations that were 
used in this study provide linear elution conditions for the given drugs on HSA columns.  
The chromatographic experiments were carried out at a typical flow rate of 0.50 mL/min 
and at a temperature of 37 °C.  All of the injected solutions and mobile phases that were 
used in the experiments were passed through 0.2 μm filters and degassed for 10-15 min 
prior to use.  
In the frontal analysis experiments with warfarin and L-tryptophan, the columns 
were first equilibrated with pH 7.4, 0.067 M potassium phosphate buffer.  Using a six-port 
valve, a switch was made from this pH 7.4 buffer to a solution containing a known 
concentration of the desired probe compound in the same buffer.  After a breakthrough 
curve had been formed and a stable plateau had been reached, a switch was made back to 
pH 7.4, 0.067 M potassium phosphate buffer to elute the retained drug or solute.  These 
frontal analysis experiments were carried out by using seven solutions that contained 1-40 
μM warfarin, with the elution of warfarin being monitored at 307 nm, and seven solutions 
containing 1-1000 μM of L-tryptophan, with elution of L-tryptophan being monitored at 
280 nm.  All these experiments were performed in triplicate or quadruplicate.  The 
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midpoint of each breakthrough curve was determined with Peak Fit 4.12 by using the 
centroid of the first derivative for the curve, following smoothing by the Savitsky-Golay 
method [33].  A correction for the system void time and for non-specific binding was made 
by subtracting the results for the control column from the results that were obtained on 
each entrapped protein column, using an approach described in previous studies [20,22].  
4.3. THEORY 
4.3.1. Zonal elution 
The global affinity of a target compound for a binding agent with several 
independent sites (e.g., as often occurs for the binding of drugs with HSA) can be described 
as the addition of the affinities for all the sites on the binding agent.  For a column that is 
made by entrapment, essentially all the binding agent will be active and the overall 
retention factor (k) of a drug or solute due to binding at these sites can be described by the 
relationship in Equation 4.1 [19], 
                   𝑘 = (𝑛1𝐾𝑎1 + 𝑛2𝐾𝑎2 + ⋯ 𝑛𝑛𝐾𝑎𝑛)𝑚𝐿𝑡𝑜𝑡/𝑉𝑚                              (4.1) 
where ni is the relative moles of binding site i for a given drug or solute per mole of protein, 
Kai is the association equilibrium constant for the same site and drug/solute, mLtot is the total 
moles of all binding sites for the solute in the column, and Vm is the column void volume.  
The global affinity in this equation is the term in parentheses and can also be represented 
by the sum of these terms, nKa’.  This is a number-weighted sum of the equilibrium 
constants for all the binding sites for the drug or solute on the immobilized binding agent 
[19]. 
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When a probe interacts with a single type of site on an entrapped binding agent, 
Equation 4.1 can be reduced to the following expression,   
                                   𝑘 = 𝐾𝑎
𝑚𝐿𝑡𝑜𝑡
𝑉𝑚
                                          (4.2) 
where Ka is the association equilibrium constant for the probe with the specific binding site 
[19]. 
Equations 4.1 and 4.2 indicate that the measured retention factor for a solute on a 
column that contains an entrapped binding agent can allow a direct determination of the 
global binding constant or site-specific binding constant for this solute.  This can be 
accomplished by using experiments like those shown in Figure 4.2.  First, an injection of a 
drug or solute that is dissolved in the buffer alone can be made onto a column containing 
the entrapped binding agent, making it possible to determine the total retention factor, ktot.  
This parameter, along with a previous measurement of the column void volume and mLtot, 
makes it possible to obtain the global affinity, as is shown in the following reduced form 
of Equation 4.1 [19], 
                                    𝑘𝑡𝑜𝑡 =
𝑛𝐾𝑎
′ 𝑚𝐿𝑡𝑜𝑡
𝑉𝑚
                                                     (4.3) 
where 𝑛𝐾𝑎
′ = ∑(𝑛𝑖𝐾𝑎𝑖). 
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Figure 4.2  Use of zonal elution experiments for estimating the global affinity (nKa’) or 
site-selective affinity (Ka1) for a solute on a column that contains an entrapped 
protein or binding agent.  Other terms in this figure are described in the text. 
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The same drug or solute can then be injected in the presence of a mobile phase that 
contains a site-selective probe (e.g., warfarin for Sudlow site I or L-tryptophan for Sudlow 
site II of HSA).  The agent added to the mobile phase is present at a level that saturates a 
known fraction of the given site in the column.  During this second injection, the retention 
for the solute will be lower because the probe in the mobile phase is binding to one of the 
sites on the entrapped agent.  The shift in retention can make it possible to find the 
association equilibrium constant for this specific binding site (Ka1), as is indicated in 
Equation 4.4. 
                             𝑘 =
(𝑛𝐾𝑎
′ −𝐾𝑎1)𝑚𝐿𝑡𝑜𝑡
𝑉𝑚
                                                    (4.4) 
The value of mLtot in Equations 4.3 and 4.4 can be obtained through independent 
frontal analysis measurements or by making a retention factor measurement with a probe 
that has a known value for its association equilibrium constant with the same binding agent.  
Repeating the experiment in Figure 4.2 with probes for other binding sites should make it 
possible to also find the solute’s affinity for each of the other binding regions [19].   
The following equations are used to obtain the experimental values of the retention 
factors that are used to estimate the overall and site-specific affinities. 
                     𝑘𝑡𝑜𝑡 =
𝑡𝑟𝑡−𝑡𝑚
𝑡𝑚−𝑡𝑣
                   (4.5)                               𝑘 =
𝑡𝑟−𝑡𝑚
𝑡𝑚−𝑡𝑣
                        (4.6)      
                                                   𝑘1 = 𝑘𝑡𝑜𝑡 − 𝑘 =
𝑡𝑟𝑡−𝑡𝑟
𝑡𝑚−𝑡𝑣
                                                (4.7) 
where trt and tr are the retention times for the injected solute in the presence of only buffer 
or the buffer plus the site-specific probe; and tm and tv are the void times of the column and 
the system (e.g., as obtained for a non-retained solute with or without a column being 
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placed in the system); and other terms are the same as defined previously.  Substituting the 
relationship for k1 that is given in Equation 4.7 and placing this into Equation 4.2 to solve 
for Ka1 gives the following combined expression. 
                                                 𝐾𝑎1 =
𝑘1𝑉𝑚
𝑚𝐿𝑡𝑜𝑡𝑎𝑙
=
(𝑡𝑟𝑡−𝑡𝑟)
(𝑡𝑚−𝑡𝑣)
𝑉𝑚
𝑚𝐿𝑡𝑜𝑡
      (4.8) 
This equation shows how a site-specific binding constant for a drug with a binding 
agent can be obtained from retention time measurements that are performed on both a 
column that contains the entrapped binding agent and a control column. 
The concentration of a site-specific probe (e.g., warfarin and L-tryptophan for 
HSA) that is needed in the mobile phase to obtain a given level of saturation for the 
entrapped binding agent can be found by using the following relationship,   
                                             
𝑘−𝑘𝑚𝑖𝑛
𝑘𝑚𝑎𝑥−𝑘𝑚𝑖𝑛
=
1
1+𝐾𝐼 [𝐼]
                                        (4.9) 
where I represents the probe,  KI is the association equilibrium constant for this probe at its 
binding site, and [I] is the concentration of the probe in the mobile phase [33].  The terms 
k, kmin and kmax are the retention factor that should result for the injected solute at a given 
concentration of the probe, the minimum possible retention factor for this solute (i.e., when 
all the given binding sites are saturated), and the maximum possible retention factor for the 
solute (i.e., when all these sites are available for binding).  
The ratio on the left of Equation 4.9 represents the relative retention that is observed 
for the solute in the presence of the competing agent.  This ratio is also related to the 
fraction of binding sites that are available to interact with the solute.  When the value of [I] 
is 0, the value of k will be equal to kmax and the ratio on the left of Equation 4.9 will be 
equal to 1.0 (or 0% site saturation).  As the value of [I] approaches infinity, the value of k 
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approaches kmin and the fraction on the left of Equation 4.9 approaches 0 (or 100% site 
saturation) [33].  It is also possible to use intermediate concentrations of the competing 
agent to produce a given shift in retention.  For instance, the concentration of the competing 
agent that is needed to reach 90% saturation at the given site on the binding agent can be 
found by setting the left side of Equation 4.9 equal to 0.1 and using the remaining terms to 
find the value of [I] that is needed to obtain this condition. 
4.3.2. Frontal analysis 
For a column with a single type of binding site for an analyte (A), Equation 4.10 
describes the relationship between the apparent moles of the applied analyte (mLapp) that 
are required to reach the mean position of the breakthrough curve [33]. 
                                             𝑚𝐿𝑎𝑝𝑝 =
𝑚𝐿𝑡𝑜𝑡𝐾𝑎[𝐴]
(1+𝐾𝑎[𝐴])
                                     (4.10) 
In this equation, mLtot is the total moles of active binding sites for the analyte in the 
column, and Ka is the association equilibrium constant for the analyte at these binding sites.  
This equation can be rearranged into the following form, which is useful for obtaining the 
moles of active binding sites through the use of a double-reciprocal plot of 1/mLapp vs 1/[A]. 
                            
1
𝑚𝐿𝑎𝑝𝑝
=
1
𝐾𝑎𝑚𝐿𝑡𝑜𝑡[𝐴]
+
1
𝑚𝐿𝑡𝑜𝑡
                            (4.11) 
The frontal analysis experiments involve applying analyte solutions of various 
concentrations to the entrapped protein columns, and measuring the values of mLapp that 
were needed to reach the central point of each breakthrough curve.  Then, using equation 
4.11, it is possible to find the total moles of binding sites for A in the column, mLtot.  The 
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value of the association equilibrium constant Ka can be obtained from the same plot, by 
using the ratio of the intercept over the slope for the best-fit line [33]. 
The range of analyte concentrations to be used in a frontal analysis experiment in 
order to cover the range of signal variation, is calculated by employing a modified version 
of Equation 4.10 [33], 
                                  
𝑚𝐿𝑎𝑝𝑝
𝑚𝐿𝑡𝑜𝑡
=
𝐾𝑎[𝐴]
(1+𝐾𝑎[𝐴])
                               (4.12) 
where all the terms are the same as defined earlier.  The left side of this equation is 
the fraction of the binding sites in the column that are bound to the analyte at a given 
concentration.  The fraction is equal to zero when no analyte is applied, and approaches 
one when the analyte concentration goes to infinity.  For achieving measurable shifts in the 
central point of the breakthrough curve, it is advisable to choose concentrations for A that 
will produce a degree of saturation for the column that is between 10% and 90%, or 
conditions that will give a value for the ratio on the left-hand side of Equation 4.12 that is 
between 0.10 and 0.90 [33]. 
4.4. RESULTS AND DISCUSSION 
4.4.1. Estimation of the amount of an entrapped protein in a column 
The amount of HSA that was entrapped in a column was determined by using both 
frontal analysis and zonal elution experiments with warfarin and L-tryptophan.  The frontal 
analysis experiments were carried out by using a 1.0 cm × 2.1 mm i.d. column that 
contained the entrapped HSA.  The application of either warfarin or L-tryptophan to this 
column gave frontal analysis results that provided a good fit to Equation 4.11 and a single-
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site binding model.  Figure 4.3 shows some examples of breakthrough curves that were 
obtained in the frontal analysis experiments with L-tryptophan.  Figures 4.4 and 4.5 show 
the double-reciprocal plots that were obtained for warfarin and L-tryptophan, respectively, 
when their data were analyzed according to Equation 4.11.  The concentrations of the 
analyte solutions that were used in these frontal analysis experiments were selected to 
provide between 10% and 90% saturation of the total binding sites, as calculated by using 
Equation 4.12. 
The total moles of protein were also estimated by using zonal elution experiments 
that were carried out with the same column and using the same analyte or probes as were 
used in the frontal analysis experiments.  The values for the moles of entrapped protein that 
were obtained by both of these methods are provided in Table 4.1.  There was good 
agreement between the two methods, with no significant difference being present at the 
95% confidence level.  This indicated that it was possible to measure the total moles of 
binding sites and protein by either method, with the zonal elution technique being preferred 
in later studies because it required much less time and reagents than the frontal analysis 
experiments. 
The value of Ka that was obtained from the double-reciprocal plot for warfarin was 
2.6 (± 0.3) × 105 M-1, which was in good agreement with an average value of 2.4 (± 0.4) 
× 105 M-1 that has been previously determined for the R- and S-enantiomers of warfarin 
with HSA.  The value of Ka that was obtained from the double-reciprocal plot for L-
tryptophan was 0.93 (± 0.23) × 104 M-1, which was also in good agreement with a value 
of 1.1 (± 0.3) × 104 M-1 that has been reported in previous studies with HSA [26,33]. 
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Figure 4.3  Frontal analysis experiments conducted with L-tryptophan being applied to a 
1.0 cm × 2.1 mm i.d. column that contained entrapped HSA.  The temperature 
of this column was 37 °C and the flow rate was 0.5 mL/min. 
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Figure 4.4 Double-reciprocal plot obtained for frontal analysis studies with warfarin on 
a 1.0 cm × 2.1 mm i.d. column containing entrapped HSA, as measured at 37 
°C and 0.5 mL/min.  The best-fit line was obtained by applying Equation 4.11 
to these data.  The inset shows the residual plot for the distribution of the data 
about the best-fit line. 
  
  
 
 
 
 
  
  
 
 
 
 
 
 
Figure 4.5  Double-reciprocal plot obtained for frontal analysis studies with L-
tryptophan on a 1.0 cm × 2.1 mm i.d. column containing entrapped HSA, as 
measured at 37 °C and 0.5 mL/min.  The best-fit line was obtained by 
applying Equation 4.11 to these data.  The inset shows the residual plot for 
the distribution of the data about the best-fit line. 
 
  
  
 
 
 
 
 
 
  
  
 
 
 
 
 
Table 4.1.  Estimates of the amount of entrapped normal HSA, as determined by zonal 
elution and frontal analysis 
Probe or 
analyte 
Column void volume, 
Vm (L × 10-5) 
Moles of entrapped protein1 
(mol × 10-8) 
Zonal elution Frontal analysis 
Warfarin 
3.35 
( ± 0.07) 
1.83 (± 0.31) 1.46 (± 0.17) 
L-Tryptophan 1.26 (± 0.35) 1.09 (± 0.27) 
 
1These values were measured at 37 °C in pH 7.4, 0.067 M phosphate buffer.  The values in 
parentheses represent a range of ± 1 S.D. 
  
 4.4.2. Estimation of global affinity constant and site-specific binding constants for 
acetohexamide with entrapped normal HSA  
Once the total moles of entrapped normal HSA had been determined, the global 
affinity constant for acetohexamide with the entrapped HSA was determined by making 
injections of acetohexamide on both the entrapped HSA column and a control column.  A 
second set of injections were then made for acetohexamide in the presence of a site-
selective probe for HSA (e.g., warfarin for Sudlow site I or L-tryptophan for Sudlow site 
II) to determine the binding constants of acetohexamide at specific sites on HSA. 
Equation 4.9 was used to determine the concentrations of the site-specific probes 
that were needed in these experiments to achieve near complete saturation of the binding 
sites.  This was done by setting the left side of Equation 4.9 equal to a relative retention of 
0.05 (representing 95% site saturation) for calculating the concentration that would 
produce a 95% shift in retention from its maximum possible value.  The known association 
equilibrium constants for HSA with warfarin and L-tryptophan (i.e., the probes that were 
used as site-selective additives in this work) were also used in these calculations.  The 
conditions needed for 95% site saturation were estimated to occur when the mobile phase 
contained 79 µM warfarin or 1.7 mM L-tryptophan.  Experiments that were also done at 
90% site saturation, which corresponded to the use of 40 µM warfarin or 850 µM L-
tryptophan in the mobile phase. 
Table 4.2 shows the association equilibrium constants that were measured by zonal 
elution for acetohexamide in the presence of various amounts of the mobile phase 
additives.   
  
 
Table 4.2.  Site-specific association equilibrium constants measured for acetohexamide 
in zonal elution experiments and using various concentrations of site-
selective probes in the mobile phase 
Probe1 
Mobile phase 
concentration 
Site-specific association equilibrium 
constant, Ka (M-1 × 104)2 
 Sudlow site I Sudlow site II 
Warfarin/L-tryptophan 101.6 µM/1.7 mM 10.9 (± 1.9) 6.9 (± 2.0) 
Warfarin/L-tryptophan 40 µM/850 µM 9.9 (± 0.18) 6.8 (± 2.0) 
Warfarin (racemate) 40 µM 8.3 (± 1.4)  N.A. 
R-Warfarin 40 µM 8.9 (± 0.9) N.A. 
1Warfarin was used as a probe for measuring the binding constant for Sudlow site I and L-
tryptophan was used for Sudlow site II.  These probes were used in separate sample solutions for 
each experiment.  Physiological conditions were also used in these measurements (i.e., pH 7.4, 
0.067 M potassium phosphate buffer and a column temperature of 37 °C). 
2The values in parentheses represent a range of ± 1 S.D. 
  
 One observation made was that there was no significant difference at the 95% 
confidence level in the association equilibrium constants that were obtained when using 
mobile phase additives that corresponded to 95% or 90% site saturation.  Given the fact 
that lower concentrations of these additives also resulted in a decrease in reagent costs and 
a lower background signal for the detector, mobile phase concentrations of 40 µM warfarin 
or 1000 µM L-tryptophan were selected for use in all subsequent zonal elution studies.  The 
global affinity constant that was obtained in these experiments and from the retention factor 
for acetohexamide was 1.96 (± 0.33) × 105 M-1, which was in good agreement with values 
of 1.2-2.0 × 105 M-1 that have been previously obtained for this drug with HSA [19-21].   
The impact of using racemic warfarin versus a single warfarin enantiomer as a 
mobile phase additive for probing Sudlow site I was also considered in this study.  
Examples of some chromatograms that were obtained in these experiments are shown in 
Figure 4.6 and the results are included in Table 4.2.  The association equilibrium constants 
that were obtained for acetohexamide at Sudlow site I when using either type of probe were 
statistically equivalent at the 95% confidence level.  From this result, it was decided that 
racemic warfarin would be used as the probe for Sudlow site I in all later experiments with 
other sulfonylurea drugs. 
  
  
 
 
 
 
 
 
Figure 4.6  Chromatograms obtained for the injection of acetohexamide onto a column 
containing entrapped HSA and in the absence or presence of R-warfarin or 
racemic warfarin in the mobile phase. 
  
  
 
 
 
 
 
 
 
  
 4.4.3. Estimation of global affinity constants and site-specific binding constants 
for sulfonylurea drugs with entrapped samples of normal or glycated HSA 
The use of on-column entrapment and zonal elution was next used to examine the 
global affinities and site-specific binding constants for various sulfonylurea drugs with 
either normal HSA or glycated HSA.  As was demonstrated previously, the total moles of 
HSA in such a column could be obtained from retention measurements that were made 
using a well-characterized probe for such a protein.  For these experiments, warfarin was 
selected as the probe for measuring mLtot because this solute has been shown in previous 
studies to have no significant change in its affinity in the presence of low-to-moderate 
levels of glycation for HSA [19,26]. 
In this section, injections of racemic warfarin were first made onto columns 
containing entrapped samples of normal HSA or glycated HSA, and onto a control column, 
to provide an estimate of the total protein content of each column.  The same columns were 
then used for the injection of samples that contained the sulfonylurea drugs acetohexamide, 
tolbutamide or gliclazide.  These injections were initially made in the presence of only 
buffer to obtain the global affinity constants for each drug with normal HSA or the samples 
of glycated HSA.  The same drugs were then injected in the presence of a mobile phase 
that contained a site-selective probe for HSA.  To examine the binding of these drugs at 
Sudlow site I, 40 µM warfarin was added to the mobile phase.  To examine the binding of 
these drugs at Sudlow site II, 1000 µM L-tryptophan was added.  The differences in the 
retention times that were seen for each drug in the presence of only buffer or in the presence 
of a known concentration of a site-specific probe were then used to calculate the site-
specific association equilibrium constants for each drug at Sudlow sites I and II.  The global 
 affinity constants and site-specific association equilibrium constants that were measured 
for these drugs at Sudlow sites I and II are summarized in Tables 4.3 through 4.5. 
Table 4.3 shows the global affinity constants that were measured for the 
sulfonylurea drugs with normal HSA or HSA with three levels of glycation: gHSA1, which 
had a modification level that was typical of that seen in prediabetes; gHSA2, which had a 
modification level corresponding to controlled diabetes; and gHSA3, which corresponded 
to advanced/uncontrolled diabetes.  For all sulfonylurea drugs, there was an increase in the 
global affinity constant when going from normal HSA to gHSA1 and a further increase 
when going to gHSA2.  However, the global affinity constant decreased when going to 
gHSA3.  The highest increase that was observed was 1.3-fold, as noted for acetohexamide 
and gliclazide with the gHSA2 sample.  However, none of these apparent differences were 
statistically significant when the standard deviations (in parentheses) were considered.  The 
global affinity constants for these drugs with normal HSA were in good agreement with 
those reported in previous studies: 16 (± 1) × 104 for acetohexamide, 10 (± 1) × 104 for 
tolbutamide, and 5.8 (± 0.2) × 104 for gliclazide [14,19,22,24].   
  
  
 
 
 
Table 4.3.  Global affinity constants obtained for various sulfonylurea drugs with 
columns containing entrapped samples of normal HSA or HSA with various 
levels of glycation 
Drug 
Global affinity constant (M-1 × 104)  
and type of HSA1 
Normal HSA gHSA1 gHSA2 gHSA3 
Acetohexamide 18.7 (± 3.4)  20.9 (± 3.9) 25.5 (± 4.7) 22.8 (± 4.4) 
Tolbutamide   9.9 (± 1.8) 11.2  (± 2.1) 13.5 (± 2.5)  12.6 (± 2.4) 
Gliclazide 4.2 (± 0.8) 5.0 (± 0.9) 6.3 (± 1.2) 5.9 (± 1.1) 
 
1These values were measured at 37 °C in pH 7.4, 0.067 M phosphate buffer.  The 
values in parentheses represent a range of ± 1 S.D.  
  
 
 
 
Table 4.4.  Association equilibrium affinity constants obtained at Sudlow site I for 
various sulfonylurea drugs with columns containing entrapped samples of 
normal HSA or HSA with various levels of glycation 
Drug 
Association equilibrium constant (M-1 × 104)  
and type of HSA1 
Normal HSA gHSA1 gHSA2 gHSA3 
Acetohexamide 10.6 (± 2.0 ) 10.9 (± 2.0) 13.4 (± 2.7) 11.3 (± 2.2) 
Tolbutamide 6.7 (± 1.2) 7.2 (± 1.3) 7.9 (± 1.6) 7.0 (± 1.3) 
Gliclazide 2.5 (± 0.5) 2.47 (± 0.5) 3.1 (± 0.6) 2.9 (± 0.5) 
 
1These values were corrected for the fact that only 90% site saturation was used.  These 
results were measured at 37 °C in pH 7.4, 0.067 M potassium phosphate buffer.  The 
values in parentheses represent a range of ± 1 S.D. 
 
  
  
 
 
Table 4.5.  Association equilibrium affinity constants obtained at Sudlow site II for 
various sulfonylurea drugs with columns containing entrapped samples of 
normal HSA or HSA with various levels of glycation. 
Drug 
Association equilibrium constant (M-1 × 104)  
and type of HSA1 
Normal HSA gHSA1 gHSA2 gHSA3 
Acetohexamide 6.4 (± 1.2) 6.7 (± 1.2) 9.9 (± 2.0) 7.9 (± 1.6) 
Tolbutamide 5.2 (± 0.9) 3.3 (± 0.7) 4.5 (± 0.9) 5.0 (± 0.9) 
Gliclazide 1.7 (± 0.3) 2.1 (± 0.4) 3.4 (± 0.7) 3.0 (± 0.6) 
 
1These values were corrected for the fact that only 90% site saturation was used.  These 
results were measured at 37 °C in pH 7.4, 0.067 M potassium phosphate buffer.  The 
values in parentheses represent a range of ± 1 S.D. 
 
  
 Tables 4.4 and 4.5 compare the sulfonylurea drugs in terms of their association 
equilibrium constants for the two main drug binding sites on HSA: Sudlow sites I and II.  
In general, an increase in these site-specific binding site constants was observed for the 
three drugs when going from normal HSA to gHSA2.  The affinity then tended to decrease 
with further glycation, as was typical of uncontrolled diabetes (gHSA3).  The binding 
constant for Sudlow site I increased by 1.3-fold for acetohexamide, 1.2-fold for 
tolbutamide and 1.3-fold for gliclazide for gHSA2 relative to normal HSA.  The binding 
constant for Sudlow site II increased by 1.5-fold for acetohexamide and 2-fold for 
gliclazide for gHSA2 relative to normal HSA.  No increase was observed in the binding 
constant at Sudlow site II for tolbutamide as a result of glycation. 
The association equilibrium constants at Sudlow site I and II were also compared 
between the various drugs.  For instance, the binding constant at Sudlow site I was higher 
than the value at Sudlow site II for acetohexamide in normal HSA as well as in all of the 
samples of glycated HSA.  The same trend was true for tolbutamide.  For gliclazide, there 
was no statistically significant difference between the values that were measured at Sudlow 
sites I and II. 
  
 4.5. CONCLUSIONS 
In this study, a novel approach was developed and tested for measuring global 
affinity constants and site-specific binding constants for drug-protein interactions.  This 
method made use of columns containing entrapped proteins.  With these columns, it was 
possible to estimate drug-protein binding constants by using relatively simple retention 
measurements for a drug in the presence of only a buffer or in the presence of a probe for 
each specific binding site that was to be studied.   
The system was applied to the sulfonylurea drugs acetohexamide, tolbutamide and 
gliclazide, which are known to bind tightly to HSA and to have interactions at both Sudlow 
sites I and II of this protein [14,19-24].  A sample of normal HSA and three samples of 
HSA with various levels of glycation were immobilized by on-column entrapment using 
the conditions that were optimized in Chapters 2 and 3 of this dissertation. 
In order to calculate the binding constants for these drugs with normal HSA or 
glycated HSA, it was necessary to also have an estimate of the total moles of active protein 
that were in each column.  This estimate was made by using both zonal elution and frontal 
analysis experiments with a probe compound (i.e., warfarin) that had known interactions 
with these proteins.  It was found that the values obtained by zonal elution were statistically 
equivalent to those measured with the more time-consuming method of frontal analysis.  
Racemic warfarin was used for this type of measurement in the later work with the normal 
HSA and glycated HSA, because it has been shown in previous studies that the affinity of 
this drug for HSA is not affected significantly by the glycation of HSA at the modification 
levels that are normally seen in diabetes [19,26]. 
 The global affinity constants for several sulfonylurea drugs were measured by this new 
approach.  Good agreement was seen between these values and those that have been previously 
estimated for these drugs with HSA.  It was also shown how site-specific association equilibrium 
constants for these drugs could be measured with either normal HSA or glycated HSA.  Good 
agreement was seen between the global affinity constants that were found in this study and 
values that have been calculated previously for the same drugs with HSA.  
The change in binding affinity of sulfonylurea drugs to HSA as a function of glycation has 
profound biological implications in terms of changes in efficacy and side-effects of the diabetes 
drugs. The rapid approach addressed in this chapter for studying protein-drug interactions by 
using entrapped proteins in HPAC columns can be applied for screening the binding of drugs with 
proteins isolated from serum of patients with some pathological condition in order to tailor the 
treatment to each individual. 
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 CHAPTER 5.                                                                 
MICROFLUIDIC DEVICES WITH ENHANCED 
FLUORESCENCE DETECTION WITH MONOLITH 
SUPPORTS AND SILVER NANOPARTICLES 
5.1. INTRODUCTION 
The systems involved in the studies addressed in the first four chapters of this 
dissertation can be classified within the normal analytical scale.  However, nanotechnology 
has opened up a new frontier for analytical sciences, leading to the development of 
microfabricated devices.  These systems can be fabricated from glass, silicon, or polymer-
based materials and fulfill the requirements for the creation of a complete “laboratory-on-
a-chip” [1].  Affinity and immunoaffinity separation techniques are well suited to 
integration into these microsystems due to the specificity and fast reaction times that can 
occur in these systems for the analytes of interest.  Affinity and immunoaffinity devices 
can be static, such as protein arrays, or can be based on microfluidics, as can occur when 
using capillary electrophoresis and chromatographic microfluidic systems [1,2]. 
One of the most appealing advantages of these microfluidics devices is the low 
limits of detection that can be attained with them, even when they are used with very small 
samples and small amounts of reagents.  This is especially true when these devices are 
combined with fluorescence detection or mass spectrometry.  This makes microfluidic 
devices attractive for use in biointeraction systems or for biomedical analysis [1,3].  The 
 development of nanomaterials (including carbon nanotubes, silica nanoparticles, gold or 
silver nanoparticles, magnetic beads, quantum dots and multifunctional core-shell systems) 
has led to approaches that may provide even greater signal intensities and higher stabilities 
in these signals at low detection limits [3-5].  For example, the increased surface areas for 
many of these materials can allow for an increase in sensitivity by providing more reaction 
centers, with some devices using nanomaterials allowing for detection in the nM or pM 
range [2,6-8]. 
Fluorescence-based detection has intrinsically high sensitivity due to the large 
extinction coefficients and quantum yields of the fluorescent labels that are in common use 
[9,10].  However, in the visible range of the electromagnetic spectrum, fluorescence 
detection suffers from interferences and frequently has a high background signal that is 
produced by autofluorescence and light scattering from biological components, membranes 
or plastics that are used in the construction of sensors or microfabricated platforms [7].   
An alternative to overcome this problem is to use near-infrared (NIR) fluorescent 
labels for detection.  NIR fluorescence involves the absorption and emission of light in the 
range of 700–900 nm.  NIR fluorescent dyes can offer better sensitivity and higher signal-
to-noise ratios than traditional fluorescent labels because the autofluorescence from 
common biological components such as proteins and cells is greatly reduced in the NIR 
region [10].  Plastics that are commonly used in detection or microfluidic systems, such as 
nitrocellulose, polyvinylidene difluoride (PVDF), poly(methylmethacrylate) (PMMA), 
and polydimethylsiloxane (PDMS), also have reduced light scattering and 
autofluorescence in the NIR region [7].  For this reason, NIR fluorescent labels have been 
of great interest for use in analyzing trace substances in biological environments [11,12]. 
 Despite their drastic reduction in interferences and background signals, NIR 
fluorophores still suffer from lower signal intensities than fluorophores in the visible range 
of the spectrum, which is caused by their low intrinsic quantum yield [13].  Thus, there 
remains a need for improved sensitivity for these dyes, in order to expand the use of NIR 
fluorescence in the biomedical and bioanalytical fields.  An approach to overcome the low 
intrinsic quantum yields of these fluorophores, and to improve the signal from NIR 
fluorescent probes, is to use plasmon-active nanostructures (e.g., made from gold or silver) 
located near but not in direct contact with the fluorophore. The close proximity of the 
nanoparticles and NIR fluorescent probe produces an effect known as surface-enhanced 
fluorescence (SEF). 
SEF occurs because metal nanoparticles (mNPs) have conduction band electrons.  
When these free electrons are subjected to an electromagnetic field at a certain frequency, 
they are forced to oscillate within the particle volume and slightly into the surrounding 
material [14].  The oscillating electron clouds, which are referred to as surface plasmons, 
act as energy collectors that can concentrate energy from a large volume (e.g., the volume 
occupied by the light beam or laser used to illuminate a NIR fluorescent probe) to the much 
smaller volume that is occupied by the nanoparticles [15].  This causes electromagnetic 
fields to be greatly increased in the regions where the mNPs are concentrated and between 
joints and clusters of mNPs.  Consequently, the excitation and emission rates of the 
fluorophore are greatly increased [16].  mNPs have been referred to as nanoantennas 
because of their ability to concentrate energy from a large space into a smaller region [17-
20].  In areas of the material where the mNPs form clusters or junctions, known as “hot-
spots”, the fluorescence intensity can be dramatically improved by SEF [21-25].  By 
 combining NIR fluorescent dyes and SEF, it is possible to improve the limits of detection 
for these dyes in fluorescence-based assays by simultaneously increasing the signal and 
reducing the background noise of the signal [26,27]. 
5.2. EXPERIMENTAL SECTION 
5.2.1. Materials 
The glycidyl methacrylate (GMA, 97% pure), ethylene dimethacrylate (EDMA, 
98%), 1-dodecanol (98%) and cyclohexanol (99%) were purchased from Sigma-Aldrich 
(St. Louis, MO, USA).  The PDMS prepolymer and curing agent were also obtained from 
Sigma-Aldrich.  Camphorquinone (99%) and ethyl-4-dimethylaminobenzoate (99%) were 
purchased from Alfa Aesar (Ward Hill, MA, USA).  All other reagents were of the purest 
grades available.  A citrate-stabilized solution of silver nanoparticles (AgNPs; 18 nM with 
an average particle diameter of 18 Å) was a gift from LI-COR Biosciences (Lincoln, NE, 
USA).  The AgNP solution was swirled and filtered through 0.20 μm nylon Acrodisc 
syringe filters (Pall, Washington, NY, USA) before use to eliminate any aggregates that 
may have formed in this preparation.  A Vivaspin ultrafiltration spin column (300 kDa MW 
cutoff; Sartorius, Götingen, Germany) was used for isolating the AgNPs from their original 
solution.  The IRDye 800 CW carboxylate dye was obtained from LI-COR Biosciences.  
All buffers and aqueous solutions were prepared using water from a Milli-QAdvantage 10 
system (EMD Millipore Corporation, Billerica, MA, USA).  The buffers were filtered 
through 0.20 μm GNWP nylon membranes from EMD Millipore prior to their use. 
 5.2.2. Solution preparation 
A solution containing the IRDye 800 CW carboxylate dye was prepared by 
combining the contents of a vial that contained 20 nmol of this dye with 0.5 mL of pH 7.4, 
0.067 M potassium phosphate buffer.  This gave a 40 µM solution of this dye that was kept 
in the freezer at -20 °C.  From this solution a diluted stock solution containing 1000 nM of 
the same dye was prepared by dilution with pH 7.4, 0.067 M potassium phosphate buffer.  
This diluted stock solution was stored at 4 °C and used within one month of preparation.  
The working standards were made from the 1000 nM dye solution by diluting them with 
pH 7.4, 0.067 M potassium phosphate buffer.  These standards were used within two days 
of their preparation.  All of these solutions were protected from the light by covering their 
vials with aluminum foil and storing the solutions in the dark. 
5.2.3. Apparatus 
Measurements of the IRDye 800 CW carboxylate dye were carried out by using the 
optical components of a 4200 near-infrared (NIR) fluorescence microscope that were 
provided by LI-COR.  This type of microscope was equipped with 680 and 780 nm diode 
laser sources that were focused into a 200 µm electron beam at a short distance from the 
detection objective lens.  When one of these lasers (modulated at 9.2 kHz) illuminates a 
sample containing an appropriate NIR fluorescent dye, some of this dye may be excited 
and its fluorescent signal is converted into an electrical signal by an avalanche photodiode 
detector.  The signal is preamplified in the detector and sent to a 4000M microscope 
controller, which was also from LI-COR.  The controller demodulates the signal and 
provides a DC analog output that is proportional to the concentration of the dye in the 
sample. 
 This optical system was mounted onto a programmable platform from National 
Aperture (Salem, NH, USA) that could be moved in the x, y and z directions.  This platform 
allowed travel up to 138 cm in any direction, with speeds up to 7.6 mm/s at a repeatability 
of 0.2 µm and with an accuracy of 0.7 µm.  This combined system was used in this research 
to scan samples that contained the NIR fluorescent dye, to measure this dye, and to examine 
the signal of this dye as a function of position in a sample or in a device that contained the 
dye’s solution (see Figure 5.1).  LabView 8.0 and a data acquisition board from National 
Instruments (Austin, TX, USA), along with programs written in-house, were used for 
recording the signal from the NIR fluorescent microscope and for controlling the movable 
platform.  A PHD Ultra syringe pump (Harvard Apparatus, Holliston, MA, USA) and a 0.5 
µL Rheodyne valve (Rohnert Park, CA, USA) were used for the delivery of samples and 
solutions to the microfluidic devices that were placed onto the movable platform. 
5.2.4. Construction of microfluidic devices 
The microfluidic chips were made by employing a PDMS prepolymer and curing 
agent, which were mixed at a ratio of 10:1 and degassed under vacuum for 1 h [28].  This 
PDMS polymerization mixture was then cast onto a master mold made of polyethylene 
through 3D printing and containing the desired form of the microchannel (e.g., 2.5 cm 
length × 200 µm width × 50 µm depth).  Next, the PDMS was thermally cured at 60 °C for 
1 h.  This combination of time and temperature was determined in this study to produce a 
stiff PDMS slab that still had enough elasticity to allow for cutting.  The slab was then 
gently peeled off of the mold, to avoid damaging the microchannel, and the excess material 
was cut away [28,29].  The PDMS surface with the microchannel and a glass slide were 
treated separately with an oxygen plasma for 30 s. Immediately after this plasma treatment, 
 the PDMS and glass slide surfaces were aligned onto each other. This combined device 
was then placed into an oven at 80 °C for 15 min to finalize the bonding of the PDMS to 
the glass slide [29,30].  The inlet and outlet of the resulting device were punched by using 
a 0.048 inch o.d. biopsy tool, and type PE-60 polyethylene tubing (0.048 inch o.d., 0.036 
inch i.d.) was inserted into the device after the holes had been made with the biopsy tool 
[31]. 
5.2.5. Monolith preparation 
Monoliths based on poly(glycidyl methacrylate-co-ethylene dimethacrylate) 
(GMA/EDMA) were prepared by photopolymerization [32].  This was begun by mixing 
all of the components shown in Table 5.1 except for the photoinitiators (i.e., 
camphorquinone and ethyl-4-dimethylaminobenzoate).  Before these components were 
mixed, the cyclohexanol and 1-dodecanol were heated in a water bath at 40 °C to get them 
into the liquid state.  The monomer ratio and the proportion of the porogenic solvents that 
were used have been previously found to be appropriate for making monoliths that can be 
used for immobilizing proteins or antibodies and for use in affinity-based columns [32,33].  
All of the components in Table 5.1 were then pipeted into a vial except the photoinitiators.  
The contents of this vial were placed onto a vortex mixer for 5 min in the dark.  The 
photoinitiators were then added and mixing was continued for another 2 min.  This mixture 
was poured onto a glass slide to form monolith layers or injected with a syringe into a 
microfluidic device.  A light source was used to irradiate this mixture with intense blue 
light (472 nm) for a total 3 min, which was divided in 30 s intervals over which a different 
section of the mixture was irradiated.  The light source was held at a distance of 1–2 cm 
from the mixture during this process.  The glass slide or microfluidic chip was then placed 
 into an UV-curing oven, where it was exposed to blue light for 10 min to complete 
photopolymerization of the monolith.  The protocol produced monoliths with enough 
mechanical stability for use in flow-based devices [30,33]. 
When curing was finished for the microfluidic devices, the tubing was taken off the 
PDMS slab and new PE-60 tubing was inserted through the inlet holes.  In the microfluidic 
devices that were made later in this chapter, more of the PDMS polymerization mixture 
was applied around the entrance points of the inlet tubes, followed by heating at 60 °C for 
1 h in an oven to cure this PDMS and to provide a good seal around the tubing.  These 
devices were then mounted onto the microscope stage, as shown in Figures 5.1 and 5.5, 
and connected with PEEK tubing to a syringe pump for the application of sample and 
solutions to the system. 
  
  
 
 
 
 
 
 
Figure 5.1 (Top) Microfluidics chip containing a 2.2 cm × 250 µm × 500 µm channel 
filled with a GMA/EDMA monolith.  (Bottom left) An x-y-z scanning 
platform that contains a mounted microfluidic chip.  (Bottom right) General 
components of the NIR fluorescence microscope stage.  In this work, the 
platform containing the microfluidic chip was located in front of the 
microscope’s objective lens. 
  
  
 
 
 
 
 
 
 
 
  
  
 
 
 
Table 5.1.  Composition of the polymerization mixture that was used with 
photoinitiation to make EDMA/GMA monoliths. 
Component (% w/w) mass (g) Volume (mL) 
GMA1 20 0.2 0.1860 
EDMA1 20 0.2 0.1902 
1-Dodecanol 48 0.48 0.5853 
Cyclohexanol 12 0.12 0.126 
Camphorquinone  0.0042  
Ethyl-4-dimethylaminobenzoate  0.0042  
 
1Monomers: GMA, glycidyl methacrylate; EDMA, ethylene dimethacrylate. 
2These photoinitiators were added in a 1% (w/w) amount versus the monomers. 
  
 5.3. THEORY 
5.3.1. Fluorescence spectroscopy 
The energy absorbed by a molecule when irradiated by light must be released to the 
environment either 1) as heat through molecular vibrations and collisions or 2) as light by 
the processes of fluorescence or phosphorescence, which occur on two very different 
timescales. Figure 5.2 shows a Jablonski diagram [34] that illustrates the mechanisms of 
fluorescence and phosphorescence.  Upon the absorption of a photon with an appropriate 
amount of energy, a molecule is initially excited from an electronic ground state (S0) to its 
first excited state (S1) over a short period of time (about 10
-15 s) [34,35].  Over a time scale 
of about 10-12 s, the molecule relaxes to the ground vibrational state of its first excited 
electronic state.  As the system relaxes, energy is released in the form of heat to the 
environment.  The molecule stays a time period of a few nanoseconds in the first excited 
state, which corresponds to the fluorescence lifetime.  Then, a photon is emitted in a process 
that again only lasts about 10-15 s [35].  Finally, the molecule releases more vibrational 
energy as heat, eventually returning to the lowest vibrational state of its ground electronic 
state.  Because of the two vibrational relaxation steps that occur during this process, the 
emitted light will have less energy (or have a longer wavelength) than the absorbed light.  
Aromatic molecules with delocalized electrons can undergo relaxation by fluorescence or 
phosphorescence.  These fluorophores may be from a natural source (e.g., tryptophan and 
naturally fluorescent proteins such as green fluorescent protein, GFP) or they can be 
synthetic in origin (e.g., Cyanine, Alexa, and Atto) [11].  
  
 
 
 
 
 
 
Figure 5.2  General scheme showing the energy states that are associated with 
fluorescence and phosphorescence.  A photon with energy hν is first absorbed 
by a molecule, causing an electron to move from a ground state (S0) to an 
excited singlet electronic state (S1).  The molecule losses some energy as heat 
as it moves to the lowest excited vibrational state in this electronic level.  In 
fluorescence, a photon is then emitted, allowing the electron to move back to 
its ground electronic state.   In phosphorescence, the excited electron instead 
first passes from the singlet state (S1) to a triplet state (T1) by means of inter-
system crossing.  The lifetime of this T1 state can be quite long (i.e.,1 ms to 
hours). Reproduced with permission from reference [34]. 
 
  
  
 
 
 
 
  
 Fluorescence spectroscopy is conducted by exciting a fluorescent compound with 
light source at an appropriate wavelength and collecting the light that is emitted at a longer 
wavelength.  The excitation source can be a laser, a light-emitting diode, or a broadband 
filament bulb that is equipped with a filter.  The wavelength difference between the 
absorption and emission maxima is known as the Stokes’ shift, and is usually 10-20 nm for 
organic-based fluorescent compounds.  This is illustrated in Figure 5.3 by using the 
absorption and emission spectra for the NIR fluorescent dye IRDye 800CW, which was 
used for the studies reported in this chapter [10,12,34,35]. 
5.3.2. Surface-enhanced fluorescence 
Surface-enhanced fluorescence (SEF) has been known for decades but only 
recently has it gained popularity within the scientific community.  This technology makes 
it possible to significantly improve the quantum yield for a fluorophore by increasing the 
excitation rate of the fluorophore as well as improving its photostability [3].  The use of 
nanoparticles to enhance optical detection started to grow more rapidly when the related 
phenomenon of surface-enhanced Raman scattering (SERS) became popular in the 
research community [36,37].  Raman scattering is important because every molecule has a 
unique scattering spectrum.  Unfortunately, Raman intensities are extremely low and, even 
with an enhancement in sensitivity, detecting this type of scattering remains an issue that 
limits the application of SERS in bioanalysis [36]. 
 
  
  
 
 
 
 
 
 
 
Figure 5.3 Absorption (red) and emission (blue) spectra for the dye IRDye 800CW in 
phosphate buffered saline.  Copyright LI-COR, Inc. by permission. 
 
  
  
 
 
 
 
 
 
  
 The fluorescence enhancement of NIR dyes has been demonstrated with gold 
nanoparticles (AuNPs) and silver nanoparticles (AgNPs) in solution and on surfaces 
[4,5,13,38].  Gold nanostructures [39-45] and silver nanostructures [24,36,37,45] have 
been used for sensors that use light in NIR region [13], as well as in SERS detectors that 
have increased sensitivity [43].  Common examples of nanostructures that are used in 
fluorescence sensors with SEF are silver and gold nanoparticles.  Plasmon resonance can 
produce fluorescence quenching or fluorescence enhancement for organic fluorophores, 
which will depend on the emission wavelength, the distance of the fluorophores to the 
metal nanoparticles, and the size of the nanoparticles [6,46-48].  Quenching usually 
dominates when the fluorophore is located at a short distance from the surface (i.e., 
typically within 5 Å) [44,49].  The plasmonic enhancement of fluorescence dominates 
when using gold and silver at greater distances [49]. 
The intrinsic fluorescence yield can be represented by the following expression 
[10,34], 
𝛾𝑒𝑚
0 = 𝛾𝑒𝑥
0 Φ0  (5.1) 
where 𝛾𝑒𝑚
0   and 𝛾𝑒𝑥
0  are the fluorescence emission rate and excitation rate, respectively.  
The term Φ0 is the quantum yield, which can be expressed as the ratio of the radiative 
decay rate to the total decay rate.  In this case, Equation 5.1 turns into Equation 5.2 
[49,50], 
𝛾𝑒𝑚
0 = 𝛾𝑒𝑥
0 ∙
𝛾𝑟
0
𝛾𝑟
0+𝛾𝑛𝑟
0   (5.2) 
where  𝛾𝑟
0 and 𝛾𝑛𝑟
0  are the radiative and non-radiative intrinsic decay rates, respectively. 
 In the presence of surface plasmons, the excitation decay rate and the radiative 
decay rate are increased to γem and γex respectively, and a new term appears for the non-
radiative decay.  This gives the following enhanced emission rate. 
𝛾𝑒𝑚 = 𝛾𝑒𝑥 ∙
𝛾𝑟
𝛾𝑟+𝛾𝑛𝑟+𝛾𝑛𝑟
0   (5.3) 
The second term in this expression is the enhanced quantum yield, Φ.  SEF can 
then be described as a combination of enhanced excitation rate and quantum yield [51]. 
𝑆𝐸𝐹 =
𝛾𝑒𝑥
𝛾𝑒𝑥
0 ∙
Φ
Φ0
   (5.4.) 
According to these equations, the fluorescence of a probe can be enhanced by 
increasing the excitation rate or the quantum yield [52].  The quantum yield cannot exceed 
unity, so there is a limit as to how much the fluorescence can be increased by this factor, 
especially for fluorophores that already have high intrinsic quantum yields.  A local 
increase in field intensity can improve the excitation rate as well as the quantum yield, and 
is dependent on the optical properties of the material that forms the nanostructure, the 
geometry of the nanostructure, the orientation of the emitter dipole, and distance between 
the emitter and the nanostructure [53]. 
 
5.4. RESULTS AND DISCUSSION 
5.4.1. Initial alignment of NIR fluorescence microscope stage 
To align the stage of the scanning platform with the optics of the NIR fluorescence 
microscope, a piece of graph paper was glued to a glass slide that was fixed to the 
 microscope stage by using double sided tape.  The graph paper served as a guide for finding 
the optimum distance between the objective of the microscope and the surface to be 
analyzed.  The microscope stage was moved in the x-y-z planes with three servo motors 
that were controlled through a program written in LabView.   
The initial signal adjustment was carried out by moving the platform in the z-axis 
until the red laser dot from the light source reflected on the surface of the paper and was 
centered in front of the objective.  The final adjustment was achieved by moving the stage 
small distances along the z-axis (i.e., between 1000 and 200 counts, with 1 mm equaling 
2800 counts) while observing the variation in the detector’s signal until a maximum output 
was achieved.   
It was observed that the background signal resulting from the light that was 
reflected and scattered by the paper’s surface reached a maximum when the objective was 
located 13.2 mm from the paper.  In the following experiments, a piece of heavyweight 
paper cut with a 13 mm width was used as a guide for setting the initial distance between 
the microscope objective and the surface of the sample.  The final distance adjustment was 
made by moving the stage along the z-axis in small increments, as described in the previous 
paragraph. 
Working solutions were prepared by taking a stock solution containing 1000 nM of 
the IR800 CW carboxylate dye and diluting it with pH 7.4, 0.067 M potassium phosphate 
buffer.  The following dye concentrations were used for the initial studies in this chapter: 
10 nM, 100 nM, 500 nM, and 1000 nM.  Five drops of each solution were applied to 
EDMA/GMA monoliths that were formed in PEEK rings that had a 0.5 cm i.d. and a 1 mm 
depth.  These monoliths were then placed onto on a glass slide.  The slide was mounted on 
 the microscope stage with double sided tape, and the signal intensity for each dye solution 
was measured with the NIR fluorescence microscope by scanning along the x-axis and 
moving the stage in front of the microscope objective.  It was found that the signal barely 
increased from the background level when looking at the 10 nM dye solution and reached 
almost the maximum level attainable by the microscope for 100 nM solution.  The 500 nM 
and 1000 nM solutions gave the maximum possible response, indicating saturation of the 
microscope amplifier.  Based on these results, the range of dye concentrations that were 
used in the following experiments was selected to be between 10 to 100 nM. 
A plastic sheet of silica gel, as is used in thin layer chromatography, was cut in 0.5 
cm wide strips and glued to a glass slide.  The slide was mounted on the microscope stage, 
and the distance between this slide and the microscope objective was adjusted to provide 
the maximum fluorescence signal.  Two drops of IR CW800 dye standards were applied 
over the top of each strip before scanning the strip along the x-axis.  The results, as 
presented in Figure 5.4, show an increasing intensity when going from the left to the right 
(i.e., from 10 nM to 100 nM dye). The result obtained when no dye solution was present is 
shown in red and included for comparison.  These results show an observable range 
between 10 and 100 nM of the IRDye 800CW dye on such a surface, with a limit of 
detection of around 10 nM.  It was also observed that the signal decreased when the scan 
was repeated for the same strip if no fresh NIR fluorescent dye solution was added.  This 
signal reduction was believed to be due to quenching by oxygen or photobleaching of the 
fluorophore [10,34]. 
The response of this system was compared with that of a benchtop 
spectrofluorometer when the same dye solutions were measured on a Cary Eclipse 
 fluorometer that was equipped with a 96-well plate reader.  No signal was detected on the 
benchtop system at dye concentrations ranging from 10 nM to 100 nM, although a signal 
was clearly seen for the 1000 nM stock solution. 
A citrate-stabilized solution of AgNPs (18 nM) was mixed with the 10 nM and 20 
nM dye standards in proportions ranging from 10 to 50% to see if the addition of these 
nanoparticles gave any change in the dye’s fluorescent signal.  However, no significant 
increase in the signal was observed under these conditions.  
  
  
 
 
 
 
Figure 5.4  (Top) Diagram showing the scan direction along the x-axis that was used for 
silica strips that were mounted on a glass slide.  (Bottom) Scan of silica strips 
at 1000 revolutions/min (0.38 mm/s; the motor velocity, in revolutions per 
min, was converted to mm/s by using the fact that 1 revolution is 64 counts 
and 1 mm is 2800 counts) with the IRDye 800CW dye being present at the 
following concentrations (from left-to-right): 10 nM, 20 nM, 40 nM, 60 nM, 
80 nM and 100 nM.  The last position on the right is for a blank that contained 
no dye.  The red tracing shows the results that were obtained for the same strip 
when no dye was present throughout the strip.  
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 5.4.2. Fluorescence measurements of IR 800CW in microchannels and monoliths 
The detection of the IR 800CW dyes in microchannels was studied by using a 
microfluidic device that was made of PDMS, as prepared in collaboration with Dr. Stephen 
Gross (Creighton University, Omaha, NE).  This type of device had a straight microchannel 
with a length of 2.2 cm and a cross section of 250 µm × 50 µm.  The microchannel was 
molded in a PDMS slab that was fixed to a glass slide.  Teflon tubing was introduced 
through holes made in the PDMS at 90° versus the glass slide and in contact with the ends 
of the microchannel.  An aluminum mounting plate with holes for directing the tubing was 
attached with screws to the microscope stage.  The microfluidic chip was fixed with tape 
to the mounting plate, with the glass slide facing towards the microscope.  The inlet tube 
was directed through a hole in the mounting plate and connected with PEEK tubing and 
adaptors to a syringe.  The outlet was connected to a vial through another hole in the 
mounting plate. The location of the microfluidic chip in this system is illustrated in Figure 
5.5. 
The distance of the microscope from the surface of the chip was initially set at 1.3 
cm.  A 100 nM solution of IRDye 800CW dye was applied to the microfluidic chip at 20 
µL/min.  The signal from the microscope was monitored while the chip was scanned in the 
x-y plane to locate the microchannel.  A camera with led illumination was used to assist in 
locating the microchannel.  In this way, the position of the laser dot could be seen on the 
computer screen, avoiding the need to look directly into the enclosure that contained the 
microscope and the stage. 
  
  
 
 
 
 
 
Figure 5.5  Schematic showing the position of the microfluidic chip relative to the 
microscope objective and the laser source.  (Left) Lateral view showing the 
location of the laser source behind the microscope objective.  (Right) Front 
view of the microfluidics chip, showing the position of the laser source and 
the reflection of the laser dot when it was crossing the microchannel.  The 
microscope objective was centered in front of the microchannel (see dotted 
circle).  The scans were made on the x-axis and crossed the microchannel. 
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 Once a position for the laser beam had been located in the middle of the chip and 
next to the microchannel, scans were made along the x-axis, as is shown in Figure 5.4.  
These scans were made with the objective located at various different distances from the 
microscope (i.e., by varying the distance along the z-axis) until a peak was observed when 
the laser crossed the monolith containing the dye solution.  The peak height became larger 
as this distance was optimized until a maximum in the response was attained.  This is 
illustrated in Figure 5.6, which shows the variation in the signal intensity that was seen 
when scanning was carried out at three slightly different distances between the objective 
and the surface along the z-axis.  In these results, the distance from the objective lens was 
smaller than the distance obtained in the previous section due to the presence of the glass 
slide that the laser has to cross before reaching the flowing dye solution.  The apparent 
reflection point of the laser on the aluminum mounting plate appeared to be shifted to the 
left of the microchannel during detection because the laser source was located to the right 
of the microscope lens at an angle of 45 ° versus the glass surface, as can be seen in Figure 
5.5. 
Different positions along the length of the microchannel were scanned, giving 
similar results at the same scan velocities.  These results indicated that the method of 
measuring the fluorescence of the IRDye 800CW dye while it was flowing through a 
microchannel with a 250 × 50 µm cross section and molded into a PDMA microfluidic 
chip was reproducible and independent of the position along the channel’s length.  Small 
irregularities in the microchannel that may have been present did not appear to affect this 
result. 
  
  
 
 
 
 
 
 
Figure 5.6  Signals obtained at scans of 1000 revolutions/min (or 0.38 mm/s) that were 
made at three distances, separated by 200 counts (or 0.071 mm), along the z-
plane from the microscope objective to the microfluidic chip surface. 
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 The effect of the scan velocity was studied by repeating the same type of scan at 
0.038 mm/s (i.e., 1/10 the velocity used in the previous scans).  The width of the peak for 
the signal as well as the height of this peak increased, with the peak height going from 
about 0.02 V to 0.06 V.  The same level in the signal was reached when the laser was fixed 
at one point over the microchannel and the flow was stopped; but there was also an 
exponential decrease in the signal over time when dye was no longer flowing through the 
microchannel. These experiments showed that the signal increased when the scan velocity 
decreased and approached a maximum initial signal when the dye solution was not flowing.  
However, this last situation also lead to a decrease in the signal over time, which probably 
occurred due to photobleaching of the fluorophore [10,54]. 
The following experiments where performed for measuring the fluorescence of the 
IR 800CW dye when it was flowing through the system.  The microfluidic device was fixed 
to the mounting stage with clamps or tape.  The position of the device was adjusted while 
a solution of 100 nM or 500 nM of the dye was passed at 20 µL/min through the 
microchannel.  The signal was scanned at a distance of 1.3 cm or less between the 
microscope objective and the microchannel to find the position of the microchannel that 
gave a maximum response.  Another distance adjustment was then made by moving the 
stage along the z-axis in increments going from 1000 counts and down 200 counts until a 
final maximum signal was reached. 
A manual injection of 0.5 µL of the dye solution was used for these experiments.  
Solutions of the dye with concentrations of 500 nM, 50 nM, 20 nM or 10 nM were injected. 
Figure 5.7 shows the results that were obtained for a 500 nM solution of the dye that was 
 injected at 5 or 20 µL/min.  At least three injections were made at each concentration of 
the dye and at each of these two flow rates. 
As can be seen in Figure 5.7, decreasing the flow rate resulted in a larger peak in a 
manner similar to what occurred from decreasing the scan rate.  The same trend was 
observed with the other concentrations of the dye that were studied.  For the 10 nM dye 
solution, the signal was only slightly distinguishable from the background noise at the 
lowest flow rate that was tested (see Figure 5.8).  By decreasing the flow rate, the time 
needed for the dye to enter and pass through the microchannel was also increased.  This 
time could be decreased further by lowering the void time of the system (e.g., by decreasing 
the length and internal diameter of the connecting tubing), which would help provide less 
band broadening when this type of device is used in chromatographic separations or 
experiments. 
The 10 nM and 20 nM solutions of the dye were mixed with the AgNP stock 
solution at various ratios to study the effect of these nanoparticles on the fluorescence 
intensity of the NIR fluorescent dye.  No fluorescence enhancement was observed under 
these conditions. 
The fluorescence of the dye was also measured in a 2 cm × 250 µm × 500 µm 
microchannel that contained a GMA/EDMA monolith, which was prepared as described 
in Sections 5.2.4 and 5.2.5.  Injections of a 0.5 µL portion of solutions with dye 
concentrations ranging from 20 nM to 500 nM were made at 20 µL/min.  The peaks that 
were obtained showed some tailing, indicating that the dye may have been interacting with 
the monolith, as can be seen in Figure 5.9.  The calibration curve for these results gave a 
linear response with a correlation coefficient of 0.9992 (r2, 0.9984).   
  
 
 
 
 
 
 
Figure 5.7 Injections of a 500 nM solution of the IR CW 800 carboxylate dye in pH 7.4, 
0.067 M potassium phosphate buffer at several flow rates and onto a 
microchannel with following dimensions:  2.5 cm × 250 µm × 50 µm. 
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Figure 5.8  Injections of the IR CW 800 carboxylate dye at several concentrations in pH 
7.4, 0.067 M potassium phosphate buffer.  Conditions: injection volume, 0.5 
µL; microchannel dimension, 2.2 cm × 250 × 50 µm; flow rate, (left) 20 
µL/min and (right) 5 µL/min. 
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Figure 5.9 (Top) Injections of 0.5 µL for several concentrations of the IR CW 800 
carboxylate dye onto a 2 cm × 500 µm × 250 µm microchannel that was filled 
a GMA/EDMA monolith and in the presence of pH 7.4, 0.067 potassium 
phosphate buffer at 20 µL/min.  (Bottom) Calibration plot obtained for these 
same results.  
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 5.4.3. Fluorescence enhancement in EDMA/GMA monoliths 
5.4.3.1. Adjustment of the fluorescence microscope controller  
To achieve an appropriate dynamic range for measuring the signal from the NIR 
fluorescence microscope, the optimum settings for the gain and offset in the microscope 
controller where varied when using the 800 nm detection channel of this system.  The 
settings were optimized while the signal was used to monitor a 20 nM solution of the IRDye 
800CW dye in pH 7.4, 0.067 M potassium phosphate buffer, which was applied at 25 
µL/min through an empty glass capillary that was mounted on the stage and over a card 
with a non-reflective black surface.  The gain and the offset settings were adjusted so that 
the output was about -0.034 V for the dye solution and -0.043 V for the background signal 
that was present when looking at the black card.  A similar background signal was obtained 
when using a capillary that contained a flowing blank solution of pH 7.4, 0.067 M 
phosphate buffer.  This approach made it possible to ensure that the signal that was being 
optimized was due to the fluorescence of the IRDye 800CW and was not due to reflected 
or scattered light.   
The voltages that were listed in the previous paragraph were located at the lower 
end of the total possible voltage range (-0.06 to 0.06 V) of the detection system, which 
allowed enough room for signals due to higher dye concentrations without being too close 
to the minimum voltage.  The gain of the controller was increased for detecting dye 
concentrations at lower levels or decreased for the analysis of higher dye concentrations 
while still keeping the voltage signal within the measurable range. 
 
 
 5.4.3.2. Preparation of monoliths with AgNP 
Several attempts were carried out to incorporate AgNPs into GMA/EDMA 
mixtures before they were polymerized for form monoliths by photoinitiation.  Because the 
aqueous solution of the citrate-stabilized AgNPs was immiscible with the other 
polymerization components, aliquots of the AgNP solution were first dried at 60 °C; 
however, it was not possible to later resuspend the AgNPs in either the polymerization 
mixture or in one of the porogens (i.e., cyclohexanol). 
In a second approach, a 18 nM solution of the AgNPs was placed into a Vivaspin 
ultrafiltration column with a 300 kDa MW cutoff and a 6 mL capacity.  The filtrating 
element in this column was a double polyethersulfone membrane, which should have been 
capable of retaining the AgNPs because their average diameter (i.e., 20 nm) was much 
larger than the sizes of molecules that are able to pass through this type of filtration 
membrane. 
The spin time that was used for ultrafitration was found to be critical.  The use of a 
time that was too long resulted in all the AgNPs sticking to the membrane; it was not 
possible to the resuspend these particles.  The use of too little time for ultrafiltration 
resulted in some of the original aqueous solution remaining in the tube, which caused 
problems when attempts were made to later place the AgNPs into an organic solvent (i.e., 
giving two phases and poor dispersion).  After several trials, it was found that the best 
approach was to spin the AgNP solution for 30 to 60 s, followed by the careful addition of 
a non-aqueous solvent (e.g., cyclohexanol) over the AgNP solution (i.e., without disturbing 
the solution) and followed by centrifugation.  The second centrifugation step of 1 min, 
expelled the remaining water and allowed to obtain a pellet of AgNPs on the bottom of the 
 tube.  Too much time yielded the AgNPs stuck to the membrane. Finally, the tube was 
inverted twice to remove the AgNP pellet and the contents were poured into another tube.  
After this new suspension had been mixed by vortexing at a high speed for 20 s, the 
resulting suspension of AgNPs in cyclohexanol appeared to be homogeneous and, when 
mixed with the rest of the components, gave a polymerization mixture that was stable for 
several days. 
Three preparations were made by using 1 mL, 3 mL or 5 mL of the original AgNP 
solution and 1 mL of cyclohexanol.  The final conditions that were used are listed in Table 
5.2.  Although it was not possible to recover all the AgNPs from the ultrafiltration tubes, 
this method was fast and did produce a suspension of AgNPs in cyclohexanol that would 
settle down very slowly and could easily be resuspended by vortex mixing. 
Pictures of the AgNP suspensions in cyclohexanol are provided in Figure 5.10 as 
well as UV/Vis spectra for the AgNPs in a 1:10 aqueous solution and for the 
AgNP/cyclohexanol suspension. The aqueous solution spectrum shows a characteristic 
maximum for AgNPs near 460 nm [5,24].  The spectrum of the AgNP/cyclohexanol 
suspension was dominated by the background after 300 nm but had a small peak at 336 
nm. 
  
  
 
 
 
 
Table 5.2. Final conditions for dispersing AgNP in cyclohexanol (CyOH) 
 1The centrifugation temperature was 25 °C. 
  
Condition 
Volume of AgNP solution 
1 mL 3mL 5 mL 
Spin time before adding CyOH 
(min) 
0.5 1.5 2.5 
Spin time after adding CyOH 
(min) 
0.5 0.75 1.0 
Conditions used for spinning (g 
× 10-3)1 
2.0 2.0 2.0 
  
 
 
 
 
 
Figure 5.10 (Top) Suspensions of AgNPs in cyclohexanol (CyOH) that were made by 
combining various volumes of a citrate-stabilized 18 nM AgNP solution 
with 1 mL of cyclohexanol.  (Bottom left) UV/Vis spectrum for a citrate 
stabilized 2 nM AgNP solution in water.  (Bottom right) UV/Vis spectrum 
for a AgNP/cyclohexanol suspension made under the conditions shown in 
Table 5.2 for a 3 mL of AgNP solution. 
 
  
  
 
 
 
 
 
 
 
  
 Monoliths based on the conditions that are listed in Table 5.1 were prepared with 
cyclohexanol that contained AgNPs.  The AgNP/cyclohexanol suspension was made 
according to the conditions that are given in Table 5.2 when starting with 3 or 5 mL of 
AgNP aqueous solutions.  Another monolith preparation was made as a control that used 
cyclohexanol but had no AgNPs present.  Sections of glass slides were covered with layers 
of adhesive tape for creating two pockets where the monolith mixtures containing AgNPs 
or no AgNPs could be cast and polymerized through photoinitiation, as described 
previously.  After this process was completed, the slide now had a monolith layer that was 
0.7 cm wide and about 1 mm thick, as shown in Figure 5.11.  
Two types of monoliths were made on each glass slide: one containing a monolith 
layer with AgNPs and the other without AgNPs.  The system that was used to conduct NIR 
fluorescent experiments with these slides was the same as depicted earlier in Figure 5.5. 
Each glass slide was fixed to the mounting stage of the system with double sided tape. A 
piece of adsorbent paper was attached to the mounting plate for collecting excess solution.  
The initial position for the microscope objective was set at 1.3 cm from the surface of the 
monoliths. 
  
  
 
 
 
 
 
 
 
Figure 5.11  Glass slide with monolith layers containing or lacking AgNPs. A solution of 
the NIR fluorescent dye was applied to the top of each monolith with a 
dropper and allowed to flow downward across the monolith.  Other 
conditions are given in the text. 
 
 
  
  
 
 
 
 
 
 
 
  
 A solution of the NIR fluorescent dye was applied with a dropper (e.g., four drops 
of 100 nM dye) to the top of each monolith and allowed to flow across the monolith through 
gravity.  The fluorescence signal was recorded and the final distance between the monolith 
and the microscope objective was adjusted by using small movements along the z-axis, as 
described earlier.  The signal was then recorded again while the dye solution was added to 
the monolith.  After making these measurements for one of the monoliths (e.g., the one 
containing AgNPs), the microscope stage was moved to the other monolith and the process 
was repeated.  The signal intensity was then compared for the monoliths with or without 
the AgNPs. 
The results of the monolith made with 3 mL of the AgNP solution can be seen in 
Figure 5.12.  After the dye solution was added to the top of each monolith and the laser 
was fixed at one spot on the monolith’s surface, there was an initial increase in the signal, 
followed by a decrease as the dye solution moved across the monolith.  The signal was 
allowed to return to the background level before adding more solution and doing the next 
measurement. Four measurements of this type were made at different spots on each 
monolith.  For a 100 nM solution of the dye, an initial increase in signal to about 0.01 V 
was obtained on both types of monoliths.  However, in the monolith with the AgNPs  the 
fluorescence signal increased further after the addition of the dye and was followed by a 
much more gradual decrease.  The overall result was that the signal after the addition of 
the dye was about two-fold larger for this monolith than for the control monolith that 
contained no AgNPs.  When the concentration of the dye was decreased to 50 nM, an even 
greater change in the initial signal and an overall increase in signal was seen for the 
monolith with AgNPs versus the control monolith, as can be seen in Figure 5.12.  
  
 
 
 
 
 
 
Figure 5.12  Fluorescence signals for solutions of the IR800CW dye that were applied to 
monolith layers containing AgNPs or no AgNPs.  The dye concentrations 
were 100 nM (Top) or 50 nM (Bottom).  The volume of the 18 nM AgNP 
stock solution that was used to make the first monolith was 3 mL. 
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 The effect of increasing the AgNP concentration in the monolith was studied with 
a glass slide that contained a monolith layer made using the conditions that are listed in 
Table 5.2 for a 5 mL AgNP solution.  The results were obtained at four different locations 
of monoliths that contained AgNPs or no AgNPs.  Some typical results are shown for a 50 
nM dye solution in Figure 5.13.  An initial increase of 0.010–0.014 V in the signal was 
obtained when the dye solution was added to the top of the monolith with AgNPs.  This 
signal increased after addition of the dye and then decreased exponentially.  On the other 
hand, the monolith with no AgNPs showed an increase of only 0.001 to 0.0015 V when the 
dye solution was added to the top of the monolith.  In this case, there was a ten-to 18-fold 
enhancement in signal on the monoliths that contained AgNPs.  It should be noted that the 
graphs of the second glass plate were obtained by using a lower gain setting in order to 
bring the signal within the measurable range. 
The fluorescence enhancement of the IRDye 800CW carboxylate dye was studied 
with a 5 nM solution and by increasing the gain of the microscope controller.  As is 
demonstrated in Figure 5.13, the signal was easily seen in the monolith with AgNPs, but it 
was not detectable in the monolith with no AgNPs.  The gain of the system for these 
experiments was close to the maximum that could be used with the instrument, but the 
results show that it was possible under these conditions to detect dye concentrations well 
below 1 nM on the GMA/EDMA monolith layer that contained AgNPs. 
  
  
 
 
 
 
Figure 5.13  Fluorescent signal of IR800 CW dye solutions that were applied to monolith 
layers containing AgNPs or no AgNPs.  The monolith with the AgNPs was 
made according to the conditions shown in Table 5.2 when using 5 mL of the 
original AgNP solution.  The dye concentrations were 50 nM (top) or 5 nM 
(bottom).  A signal due to the 5 nM dye solution was not detectable on the 
monoliths that did not contain AgNPs. 
  
  
 
 
 
 
 
  
-0.056
-0.051
-0.046
-0.041
-0.036
0 50 100 150 200
V
Time (s)
With AgNP
Without AgNP
-0.05
-0.03
-0.01
0.01
0.03
0 50 100 150 200 250 300
V
Time (s)
-0.0555
-0.055
-0.0545
-0.054
20 40 60 80
V
Time (s)
 5.4.4. Fluorescence enhancement by AgNPs for monoliths in microfluidic chips 
The fluorescence enhancement in EDMA/GMA monoliths containing AgNPs was 
next examined by using these monoliths in microfluidic devices.  PDMS microfluidic 
devices were designed and produced for this work, as described in Section 5.2.4.  These 
microfluidic devices were placed onto the microscope mounting stage, according to the 
procedures given in Section 5.4.2.  Polymerization mixtures for the monoliths were made 
according to the conditions in Table 5.2 that used 5 mL of the original AgNP solution.  A 
control monolith was made under the same conditions but without AgNPs.  These mixtures 
were injected into the microchannel of each microchip by using a syringe, and 
polymerization was conducted as described previously.   
When the dye solutions were first applied to these microfluidic channels, leaking 
occurred at cracks that were next to the inlet holes or over the body of the PDMS chip.  
These problems were caused by the backpressure that was generated by the monolith in the 
microchannel, and were exaggerated by the fact that the flow stream approached the 
monolith at a 90 ° angle.  In an attempt to minimize or eliminate this issue, the cross section 
of the microchannel was increased to 250 × 500 µm and the inlet tube was placed at an 
angle of approximately 45° to the channel.  These modifications reduced the problems with 
leaking but did not eliminate them completely. 
As a result, a new design for the microfluidic chips, as inspired by the experiments 
with the monolith layers in the previous section, was next devised.  These microchips were 
made in collaboration with Dr. Stephen Morin’s lab and contained two micro-chambers 
with dimensions of 2 mm length × 1 mm width × 100 µm depth.  These two chambers were 
connected to PE-60 tubing at the inlets.  Monolith polymerization mixtures containing 
 AgNPs (made according to the conditions in Table 5.2 for a 5 mL AgNP solution) or 
without AgNPs were injected into these chambers with a syringe and through the inlet 
tubing.  Photoinitiated polymerization was then carried out, and the inlets were connected 
to a syringe pump, as described previously.  The design of this device, as shown in Figure 
5.14, allowed for lower back pressures to be obtained because the flow path was straight 
from the inlet to the outlet and the monolith had a larger cross section. After their 
preparation, the monolith chambers were washed for 15 min with pH 7.4, 0.067 M 
potassium phosphate buffer at 50 µL/min.  The optimum distance for detecting a flowing 
100 nM IR 800CW dye solution was then determined by moving the stage versus the 
microscope objective along the z-axis.  Next, 0.5 µL injections were made for solutions 
containing 0.5 to 100 nM of the IR 800CW NIR dye at 50 µL/min.  This design allowed 
for a rapid adjustment of the relative position of detection for comparing the response 
between the monoliths with and without AgNPs. 
  
  
 
 
 
 
 
Figure 5.14  PDMS microfluidic chip containing monoliths with or without AgNPs and 
for use in the detection of IRDye 800CW in a flowing stream.  (Top) Side 
view showing the entrance of the polyethylene tubes next to the glass slide, 
and the thickness of the PDMS plate.  (Bottom) Front view showing the 
monolith filled with AgNPs and the control monolith with no AgNPs present.  
The size of monoliths were 2 mm long × 1 mm wide × 100 µm thick. 
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Figure 5.15 Comparison of the response versus time that was obtained by injecting IRDye 
800CW solutions at various concentrations into the monoliths that were made 
with AgNPs or without AgNPs.  Conditions: dye concentrations, (top) 60 nM 
or (bottom) 80 nM; injection volume, 0.5 µL; flow rate, 0.5 µL/min. 
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 These results showed an effective fluorescence enhancement for the detection of 
the NIR fluorescent dye by using the AgNPs.  This enhancement was most noticeable when 
comparing the peak areas that were obtained (see Figure 5.15). The observed trends were 
similar to those obtained for monolith layers (see Section 5.4.3).  The fluuorescence 
enhancement made it easier to detect the dye at low concentrations.  For instance, the 
minimum concentration that could be detected for the NIR fluorescent dye in the presence 
of the AgNPs was 1 nM, whereas it was 5 nM without the use of AgNPs. 
To estimate the amount of fluorescence enhancement that was obtained, the average 
peak areas for three injections were determined for each monolith and at each dye 
concentration.  The peak area ratios that were measured both with and without the use of 
AgNPs were next determined at each dye concentration.  The resulting enhancements in 
the fluorescence were between 1.5- and 2.5-fold.  Calibration plots of area vs. concentration 
were also obtained for both types of monoliths.  The correlation factors for these plots were 
high (r2 > 0.95).  The ratio between the slopes of the best-fit lines for the monoliths with 
and without AgNPs was 1.9, which again indicated a two-fold fluorescence enhancement 
with the monolith that contained AgNPs. 
  
 5.5. CONCLUSIONS 
Detection of a model dye was achieved by using a NIR fluorescence microscope 
that was equipped with a laser light source and an x-y-z movable platform.  This system 
was used for scanning and detecting fluorescence of the dye IR 800CW in microchannels, 
capillaries, monoliths, and monolith layers.  This platform could be used in the future for 
biointeraction systems based on microfluidic chips or affinity microcolumns that contain 
monoliths based on GMA/EDMA, as has been previously demonstrated for the 
immobilization of proteins such as HSA and AGP [32,33,55].  With the scanning 
capabilities of this system, it was found that on-line detection could be carried out at several 
points along a microchannel, which makes this method useful for on-column or post-
column detection. 
The addition of AgNPs to the GMA/EDMA monoliths, by mixing the AgNPs with 
the porogen before polymerization, allowed for fluorescence enhancement of the IRDye 
800CW.  The results obtained in monolith layers that contained AgNPs showed at least a 
ten-fold enhancement in signal at the highest concentration of AgNPs that was tested.  The 
signal was also more stable with the monoliths that had AgNPs than without AgNPs.  The 
minimum concentration of the fluorophore that could be detected was improved from 10 
nM without AgNPs to less than 1 nM with the highest concentration of AgNPs used.  Even 
lower detection limits may be achieved by further increasing the AgNP content in the 
monoliths and by further optimizing the detection parameters for the microscope system.  
The fluorescence enhancement in a flow-based system was studied by injecting a 
plug of NIR fluorescent dye into a microfluidic chip that contained microlayers of 
 GMA/EDMA.  The results showed the same trend as with the dye solutions that were 
applied directly to the monolith layers.  The AgNPs had the effect of increasing the 
fluorescence and producing a more stable signal.  As a result of having a more stable signal, 
a better correlation between peak areas and the dye’s concentration was also achieved.  The 
detection limit was reduced from 5 nM to 1 nM in the presence of the AgNPs, with about 
a two-fold fluorescence enhancement being achieved when using monolith that contained 
AgNPs. 
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 CHAPTER 6.                                                              
SUMMARY AND FUTURE WORK 
6.1. SUMMARY 
The entrapment method for immobilizing biologically-related compounds in 
chromatographic supports has been shown to be useful for preparing affinity ligands where 
the ligand retains essentially full activity.  The work in this dissertation included the 
development of new approaches for increasing the amount of proteins that can be placed 
in supports prepared by entrapment for high performance affinity chromatography (HPAC) 
and the application of the newly developed supports for studying the interactions between 
drugs and proteins.  As shown in this dissertation, HPAC with supports made by 
entrapment can be used to investigate how the binding of proteins to drugs and small 
solutes is affected by glycation.  The use of microfluidics in HPAC and with monolithic 
supports and using metal-based fluorescence enhancement for detection was also 
considered. 
The first chapter provided a general introduction to HPAC and the methods of zonal 
elution and frontal analysis.  Background information on the entrapment method was also 
provided, along with a description of the potential advantages of this method over covalent 
immobilization methods. 
Chapter 2 examined ways of increasing the protein coverage, and therefore the 
overall activity, of supports made by entrapment.  This work included modifying the 
conditions of the entrapment process in a slurry-based format.  Human serum albumin 
 (HSA) was used as a model protein for these studies.  The protein content for several 
batches of silica supports that were made by entrapment was measured and the retention of 
HPLC columns that were made with these supports was measured for solutes that bind to 
HSA.  Alternative ways of measuring the protein content of such supports, such as 
fluorescence of labelled HSA and thermogravimetric analysis, were investigated as well. 
Chapter 3 dealt with the development of a flow-based format for the entrapment of 
proteins.  The optimum conditions for obtaining supports with high protein contents with 
this on-column entrapment method were found.  The supports that were made by this 
method were used in the study of interactions between HSA or lectins and probe 
compounds that are known to bind these proteins.  By using probes with known binding 
constants for these proteins, it was possible to estimate the protein content of these supports 
in columns without the need for disassembling these columns or destroying the support. 
Changes in the bloodstream can occur during metabolic diseases, such as diabetes, 
and produce modifications in serum proteins.  One important example is the glycation of 
HSA that occurs in diabetes.  This modification can influence the binding of this protein 
with some drugs, such as many sulfonylurea drugs that are used to treat type II diabetes.  
In Chapter 4, samples of normal HSA and HSA with glycation levels characteristic of 
patients with pre-diabetes, controlled diabetes or advanced diabetes were placed into 
supports made by entrapment and the on-column method.  The high protein contents that 
were achieved by the on-column method, and the fact that the activity of this protein was 
maintained in these supports, allowed the use of this method in a simplified approach for 
measuring drug-protein interactions at specific sites on normal HSA or glycated HSA.  This 
 was achieved by using competing agents for the given sites and measuring the shifts in 
retention that occurred for a given drug in the presence of this competing agent. 
The development of a microfluidic device that was suitable for use in on-column 
or post-column detection in HPAC was discussed in Chapter 5. A monolith based on 
glycidyl methacrylate-ethylene dimethacrylate (GMA/EDMA) co-polymer was placed into 
such a device for use as a chromatographic support and a near infrared scanning 
fluorescence microscope was used as the detector.  The conditions that were needed with 
this system for measuring a NIR fluorescent dye were established when using monoliths 
and when the monoliths were placed into microchannels. This chapter also examined the 
fluorescence enhancement that was obtained for the NIR fluorescent dye when silver 
nanoparticles (AgNPs) were added to GMA/EDMA monoliths. The limit of detection was 
decreased for monoliths contained AgNPs when compared to monoliths without AgNPs. 
Overall, these results indicated that fluorescence enhancement by AgNPs was feasible in 
microfluidic devices containing EGA/EDMA monoliths. These devices are attractive for 
future use in biointeraction systems that may contain proteins or antibodies that are 
immobilized into monolithic supports. 
6.2. FUTURE WORK 
The work in this dissertation involved the development of high capacity supports 
containing entrapped proteins for use in HPAC.  This work has shown that an on-column 
method of entrapment can provide the highest protein contents in column affinities while 
also having minimal reagent consumption.  The creation of encapsulated protein columns 
with high protein contents has opened up many possible options for further implementation 
 of the entrapment immobilization method.  For example, it should be feasible to study 
analytes with low affinities by using columns with high protein coverage or to reduce the 
column size for studying the interactions of drugs or metabolites with proteins that are 
either expensive or that are isolated from a small amount of a sample (e.g., a serum sample 
from a human or animal).  It should also be possible with these small columns to combine 
several columns together in microfluidic devices and to use them with fluorescence 
detection to analyze samples with sizes in the sub-microliter range and target analytes at 
sub-nanomolar concentrations. 
The next logical step, after the implementation of the on-column method of 
entrapment in this dissertation, would be the automation of the entrapment process.  This 
could be done by using a system of pumps for applying the reagents through a hydrazide-
activated silica column, and a system of valves that can switch between the various reagent 
solutions.  One further step in automation would be to make a complete on-line entrapment 
system where the protein that is to be entrapped (e.g., HSA) could also be isolated from a 
biological sample (e.g., human serum) by using an antibody column for the protein, 
followed by elution of the captured protein directly into the hydrazide-activated silica 
support, where entrapment is then performed.  Such a system would minimize loss of the 
protein during sample handling steps and would provide a convenient way of entrapping 
proteins or other biologically-related agents that are obtained from in vivo samples. 
The fact that the protein remains fully active when it is immobilized by entrapment 
should also make it possible with this method to create fast screening methods that can be 
used to obtain the binding affinities for solutes with the entrapped proteins.  As shown in 
Chapter 4, this might be accomplished by simply measuring retention time shifts when this 
 solute is injected in the presence or absence of the entrapped protein.  The entrapment 
method could also be extended to additional ligands besides those examined in this 
dissertation.  Examples include other serum proteins (e.g., variants of the protein α1-acid 
glycoprotein) or other lectins (e.g., jacalin or Sambucus nigra agglutinin).  These lectin 
columns could be used in studies for glycoproteomics in which the binding of the entrapped 
lectins might be used for the isolation of glycopeptides or glycans prior to the analysis of 
these analytes by methods such as mass spectrometry. 
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